{"content":"<li class=\"n-box-item date-title\" data-end=\"1502769599\" data-start=\"1502683200\" data-txt=\"Monday, December 23, 2019\">Monday, August 14, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3289306\" data-ts=\"1502753408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289306-raymond-james-upcoming-watch-release-critical-to-fitbit-profits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James: Upcoming watch release critical to Fitbit profits</a></h4><ul>   <li>Fitbit (<a href=\"http://seekingalpha.com/symbol/FIT\" target=\"_blank\">FIT</a> <font color='green'>+2.2%</font>) is nearing the launch of the follow-up to last year's Blaze watch, and the new release will be a <a href=\"http://www.barrons.com/articles/fitbit-it-all-hinges-on-the-watch-says-raymond-james-1502749694\" target=\"_blank\">high-stakes product</a> for the company's profitability, says Raymond James.</li>    <li>Smartwatches are now where smartphones were in 2009, says analyst Tavis McCourt (reiterating an Outperform rating),  \"just recently allowing third-party app access to the platform&rdquo; and \"waiting for a 'killer app&rsquo;.\"</li>    <li>Categories of wearables are beginning to merge, and McCourt expects older Fitbit products to wane: \"Our estimate is ~20% decline in legacy products next year, and a 10-15% penetration of the base with the new smartwatch, but obviously results could come in much better or much worse than these estimates.&rdquo;</li>    <li>There's a wide range of outcomes for Fitbit and it's frustrating to track due to extremely variable third-party sales data, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289306\" data-linked=\"Raymond James: Upcoming watch release critical to Fitbit profits\" data-tweet=\"$FIT - Raymond James: Upcoming watch release critical to Fitbit profits https://seekingalpha.com/news/3289306-raymond-james-upcoming-watch-release-critical-to-fitbit-profits?source=tweet\" data-url=\"https://seekingalpha.com/news/3289306-raymond-james-upcoming-watch-release-critical-to-fitbit-profits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289304\" data-ts=\"1502752355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWX\" target=\"_blank\">TWX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289304-annabelle-sequel-tops-lackluster-box-office-weekend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Annabelle&#39; sequel tops lackluster box-office weekend</a></h4><ul>   <li>Horror film <i>Annabelle: Creation</i> (<a href=\"http://seekingalpha.com/symbol/TWX\" target=\"_blank\">TWX</a> <font color='green'>+0.4%</font>) took the biggest piece of a still-shrinking summer box office pie over the weekend, easily outpacing holdovers and a children's animated film.</li>    <li>Overall, the top 12 films brought a <a href=\"http://www.boxofficemojo.com/news/?id=4315&amp;p=.htm\" target=\"_blank\">combined $103.8M</a>, Box Office Mojo notes -- down 6% from last weekend and setting the cumulative 2017 summer at 12% below last year's pace.</li>    <li>The <i>Annabelle</i> sequel drew $35M, clearing <i>Dunkirk's</i> (NYSE:<a href='https://seekingalpha.com/symbol/TWX' title='Time Warner Inc.'>TWX</a>) fourth-week $10.9M, as well as Open Road's <i>The Nut Job 2: Nutty by Nature,</i> which debuted with just $8.3M.</li>    <li>Stephen King adaptation <i>The Dark Tower</i> (<a href=\"http://seekingalpha.com/symbol/SNE\" target=\"_blank\">SNE</a> <font color='green'>+0.4%</font>) was in the No. 4 spot with $7.8M while <i>Girls Trip</i> (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='green'>+1.9%</font>) rounded out the top five, with $6.5M.</li>    <li><i>Dunkirk</i> raised its cumulative domestic gross to $153.2M, and its worldwide total to $363.7M. Meanwhile, another film opening this weekend, <i>The Glass Castle</i> (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color='red'>-0.8%</font>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color='red'>-0.1%</font>) hit just the No. 9 slot with $4.7M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289304\" data-linked=\"&#39;Annabelle&#39; sequel tops lackluster box-office weekend\" data-tweet=\"$TWX $TWX $LGF.A - &#39;Annabelle&#39; sequel tops lackluster box-office weekend https://seekingalpha.com/news/3289304-annabelle-sequel-tops-lackluster-box-office-weekend?source=tweet\" data-url=\"https://seekingalpha.com/news/3289304-annabelle-sequel-tops-lackluster-box-office-weekend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289290\" data-ts=\"1502747985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YY\" target=\"_blank\">YY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289290-yy-off-2_3-on-new-463m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">YY off 2.3% on new $463M share offering</a></h4><ul>   <li>YY (<a href=\"http://seekingalpha.com/symbol/YY\" target=\"_blank\">YY</a> <font color='green'>+2.1%</font>) is <font color='red'>2.3% lower</font> after hours in U.S. trading following news that it's launching an <a href=\"https://seekingalpha.com/pr/16915355-yy-inc-announces-proposed-offering-5750-000-american-depositary-shares\" target=\"_blank\">offering of 5.75M American depositary shares</a>.</li>    <li>That's about $463M worth as of today's closing. Each of those ADS represents 20 Class A common shares of the Chinese firm.</li>    <li>Underwriters get a 30-day greenshoe option to buy up to an additional 862,500 ADS to cover overallotments.</li>    <li>The company will use proceeds for general purposes and debt repayment.</li>    <li>Joint book-runners are Credit Suisse USA, Goldman Sachs Asia, andj China Renaissance Securities.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289290\" data-linked=\"YY off 2.3% on new $463M share offering\" data-tweet=\"$YY - YY off 2.3% on new $463M share offering https://seekingalpha.com/news/3289290-yy-off-2_3-on-new-463m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3289290-yy-off-2_3-on-new-463m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289276\" data-ts=\"1502746599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289276-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a> <font color='green'>+16.1%</font>. <a href='https://seekingalpha.com/symbol/EXTR' title='Extreme Networks, Inc.'>EXTR</a> <font color='green'>+9.1%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='green'>+7.3%</font>. <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+5.8%</font>. <a href='https://seekingalpha.com/symbol/SYF' title='Synchrony Financial'>SYF</a> <font color='green'>+4.6%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a> <font color='red'>-15.7%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='red'>-5.5%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='red'>-4.8%</font>. ETP <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a> <font color='red'>-2.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289276\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$FATE $EXTR $WPRT - After Hours Gainers / Losers https://seekingalpha.com/news/3289276-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3289276-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289264\" data-ts=\"1502745303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMLS\" target=\"_blank\">CMLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289264-cumulus-mediaplus-28-after-q2-revenues-beat-profits-grow-fivefold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cumulus Media +28% after Q2 revenues beat, profits grow fivefold</a></h4><ul>   <li>Nanocap Cumulus Media (<a href=\"http://seekingalpha.com/symbol/CMLS\" target=\"_blank\">CMLS</a> <font color='green'>+1.2%</font>) has <font color='green'>gained 27.9%</font> after hours following the release of <a href=\"https://seekingalpha.com/news/3289131-cumulus-media-eps-line-beats-revenue\" target=\"_blank\">Q2 earnings</a> where it grew revenues slightly but quintupled net income.</li>    <li>EBITDA of $67.4M was up 6.7% Y/Y and beat an expected $60.3M.</li>    <li>Net revenue by segment: Radio Station Group, $208.6M (down 0.7%); Westwood One, $81.2M (up 6.1%); Corporate and other, $701,000 (up 0.3%).</li>    <li>Net income by segment: Radio Station Group, $46.8M (up 0.9%); Westwood One, $10.98M (up $10.09M from year ago).</li>    <li>Capex was $7.5M for the quarter (up 2.3%). Cash and equivalents came to $141.2M, up 7.6% Y/Y.</li>    <li><a href=\"https://seekingalpha.com/pr/16915146-cumulus-reports-operating-results-second-quarter-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289264\" data-linked=\"Cumulus Media +28% after Q2 revenues beat, profits grow fivefold\" data-tweet=\"$CMLS - Cumulus Media +28% after Q2 revenues beat, profits grow fivefold https://seekingalpha.com/news/3289264-cumulus-mediaplus-28-after-q2-revenues-beat-profits-grow-fivefold?source=tweet\" data-url=\"https://seekingalpha.com/news/3289264-cumulus-mediaplus-28-after-q2-revenues-beat-profits-grow-fivefold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289243\" data-ts=\"1502744371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSLP\" target=\"_blank\">MSLP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289243-musclepharm-q2-sales-down-20-loss-narrows-cash-balance-down-27\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MusclePharm Q2 sales down 20%; loss narrows; cash balance down 27%</a></h4><ul><li>MusclePharm (<a href='https://seekingalpha.com/symbol/MSLP' title='MusclePharm Corp.'>OTCQB:MSLP</a>) <a href=\"https://seekingalpha.com/pr/16915226-musclepharm-reports-2017-second-quarter-financial-results\" target=\"_blank\">Q2 results </a>($M): Revenue: 26.2 (-20.4%); Net Loss: (3.1) (+26.2%); Loss/Share: (0.23) (+52.1%).</li><li>Cash balance: 3.6 (-26.5%).</li><li>Shipped first product from Natural Series line.</li><li>Manufacturing ramped in Europe. Two new customers: Tropicana and Muscle Finesse.</li><li>Cost reduction activities: reduced inventory over 28%, operating expenses cut almost 18%, professional fees cut over 58%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289243\" data-linked=\"MusclePharm Q2 sales down 20%; loss narrows; cash balance down 27%\" data-tweet=\"$MSLP - MusclePharm Q2 sales down 20%; loss narrows; cash balance down 27% https://seekingalpha.com/news/3289243-musclepharm-q2-sales-down-20-loss-narrows-cash-balance-down-27?source=tweet\" data-url=\"https://seekingalpha.com/news/3289243-musclepharm-q2-sales-down-20-loss-narrows-cash-balance-down-27\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289239\" data-ts=\"1502744322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXTR\" target=\"_blank\">EXTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289239-extreme-networks-jumps-10-after-q4-beat-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Extreme Networks jumps 10% after Q4 beat, strong guidance</a></h4><ul>   <li>Extreme Networks (<a href=\"http://seekingalpha.com/symbol/EXTR\" target=\"_blank\">EXTR</a> <font color='green'>+8%</font>) is <font color='green'>up another 10%</font> after hours following <a href=\"https://seekingalpha.com/news/3289136-extreme-networks-beats-0_05-beats-revenue\" target=\"_blank\">fiscal Q4 results</a> where it swung to a better profit than expected and issued strong guidance for the start of its new fiscal year.</li>    <li>Revenues rose 28% and EPS gained 70% to $0.17. Operating margin was 12.2% on a non-GAAP basis, 360 basis points better than the prior year's Q4.</li>    <li>Gross margin, meanwhile, improved 480 basis points (9%) to 56.9%.</li>    <li>Revenue breakout: Product, $140.8M (up 33%); Service, $38M (up 12%).</li>    <li>Cash and investments came to $130.5M at quarter's end, up $36.4M Y/Y. Inventory ending the quarter was $45.9M.</li>    <li>For Q1 the company is targeting $200M-$210M in revenues (well above consensus for $168M), non-GAAP gross margin of 55.5%-57.5%, opex of $105M-$109M and EPS of $0.11-$0.17 (above an expected $0.08).</li>    <li><a href=\"https://seekingalpha.com/pr/16915183-extreme-networks-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289239\" data-linked=\"Extreme Networks jumps 10% after Q4 beat, strong guidance\" data-tweet=\"$EXTR - Extreme Networks jumps 10% after Q4 beat, strong guidance https://seekingalpha.com/news/3289239-extreme-networks-jumps-10-after-q4-beat-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3289239-extreme-networks-jumps-10-after-q4-beat-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289230\" data-ts=\"1502744039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BETR\" target=\"_blank\">BETR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289230-slump-continues-amplify-snack-brands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Slump continues at Amplify Snack Brands</a></h4><ul><li>Amplify Snack Brands (NYSE:<a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a>)&nbsp;<font color='red'>fell 9%</font>&nbsp;on heavy volume as investors continue to lose faith in the food company.</li><li>Shares hit a new all-time low of $6.89 in the last few minutes of trading. Amplify is down 29% since issuing profit guidance below expectations last week.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286792-light-guidance-amplify-snack-brands\" target=\"_blank\">Light guidance from Amplify Snack Brands</a> (Aug. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289230\" data-linked=\"Slump continues at Amplify Snack Brands\" data-tweet=\"$BETR $BETR-OLD - Slump continues at Amplify Snack Brands https://seekingalpha.com/news/3289230-slump-continues-amplify-snack-brands?source=tweet\" data-url=\"https://seekingalpha.com/news/3289230-slump-continues-amplify-snack-brands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289224\" data-ts=\"1502743839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289224-pareteum-beats-0_17-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum beats by $0.17, beats on revenue</a></h4><ul><li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>): Q2 EPS of -$0.10 <font color='green'>beats by $0.17</font>.</li><li>Revenue of $3.24M (-0.9% Y/Y) <font color='green'>beats by $0.09M</font>.</li><li>Shares <font color='green'>+2.5%</font>.</li><li><a href=\"https://www.sec.gov/Archives/edgar/data/1084384/000114420417043067/v471991_10q.htm\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289224\" data-linked=\"Pareteum beats by $0.17, beats on revenue\" data-tweet=\"$TEUM - Pareteum beats by $0.17, beats on revenue https://seekingalpha.com/news/3289224-pareteum-beats-0_17-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3289224-pareteum-beats-0_17-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289222\" data-ts=\"1502743832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRB\" target=\"_blank\">CLRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289222-cellectar-biosciences-beats-0_01\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectar Biosciences beats by $0.01</a></h4><ul><li>Cellectar Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a>): Q2 EPS of -$0.23 <font color='green'>beats by $0.01</font>.</li><li>Cash and equivalents  of $8.3M.</li><li>Shares <font color='green'>+9.8%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16915305-cellectar-biosciences-reports-second-quarter-2017-financial-corporate-performance\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289222\" data-linked=\"Cellectar Biosciences beats by $0.01\" data-tweet=\"$CLRB - Cellectar Biosciences beats by $0.01 https://seekingalpha.com/news/3289222-cellectar-biosciences-beats-0_01?source=tweet\" data-url=\"https://seekingalpha.com/news/3289222-cellectar-biosciences-beats-0_01\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289204\" data-ts=\"1502743104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289204-fibrogen-launches-300m-stock-offering-shares-down-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen launches $300M stock offering; shares down 1% after hours</a></h4><ul><li>FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>) slips&nbsp;<font color='red'>1%</font>&nbsp;after hours on average volume after it <a href=\"https://seekingalpha.com/pr/16915269-fibrogen-inc-announces-proposed-follow-offering-common-stock\" target=\"_blank\">announced</a> plans for a $300M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Net proceeds will fund the expansion of product development, manufacturing and commercialization activities and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289204\" data-linked=\"FibroGen launches $300M stock offering; shares down 1% after hours\" data-tweet=\"$FGEN - FibroGen launches $300M stock offering; shares down 1% after hours https://seekingalpha.com/news/3289204-fibrogen-launches-300m-stock-offering-shares-down-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3289204-fibrogen-launches-300m-stock-offering-shares-down-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289194\" data-ts=\"1502742773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRK.A\" target=\"_blank\">BRK.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289194-synchrony-financial-up-3-after-berkshire-hathaway-discloses-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchrony Financial up 3% after Berkshire Hathaway discloses stake</a></h4><ul><li>The <a href=\"https://www.sec.gov/Archives/edgar/data/1067983/000095012317007953/xslForm13F_X01/form13fInfoTable.xml\" target=\"_blank\">latest 13F</a> from Berkshire Hathaway (<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway A'>BRK.A</a>, <a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a>) shows a 17.5M share stake in the roughed-up credit card issuer (shares&nbsp;<font color='red'>down 18%</font>&nbsp;YTD). The filing also shows Berkshire exited its <a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> stake over the last quarter. Synchrony (NYSE:<a href='https://seekingalpha.com/symbol/SYF' title='Synchrony Financial'>SYF</a>) was spun out of GE about three years ago; shares are&nbsp;<font color='green'>up 2.9%&nbsp;</font>after hours.</li><li>The 13F also shows a new 18.6M share stake in Store Capital (NYSE:<a href='https://seekingalpha.com/symbol/STOR' title='STORE Capital'>STOR</a>) - an investment that had been announced in late June.</li><li>Boosted stakes for Berkshire: Bank of New York (NYSE:<a href='https://seekingalpha.com/symbol/BK' title='The Bank of New York Mellon Corporation'>BK</a>), <a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a>, and Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>).</li><li><a href=\"https://www.sec.gov/Archives/edgar/data/1067983/000095012317005259/xslForm13F_X01/form13fInfoTable.xml\" target=\"_blank\">13F three months earlier</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289194\" data-linked=\"Synchrony Financial up 3% after Berkshire Hathaway discloses stake\" data-tweet=\"$BRK.A $BRK.A $BRK.B - Synchrony Financial up 3% after Berkshire Hathaway discloses stake https://seekingalpha.com/news/3289194-synchrony-financial-up-3-after-berkshire-hathaway-discloses-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3289194-synchrony-financial-up-3-after-berkshire-hathaway-discloses-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289190\" data-ts=\"1502742652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXFD\" target=\"_blank\">OXFD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289190-oxford-immunotec-to-sell-2_5m-ordinary-shares-to-btig\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oxford Immunotec to sell 2.5M ordinary shares to BTIG</a></h4><ul><li>UK-based Oxford Immunotec (NASDAQ:<a href='https://seekingalpha.com/symbol/OXFD' title='Oxford Immunotec Global PLC'>OXFD</a>) <a href=\"https://seekingalpha.com/pr/16915266-oxford-immunotec-global-plc-announces-agreement-sell-2500-000-ordinary-shares\" target=\"_blank\">inks a deal</a> with BTIG, LLC to sell it 2.5M ordinary shares plus an option to purchase up to 375K additional shares at an undisclosed price. Net proceeds will fund working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289190\" data-linked=\"Oxford Immunotec to sell 2.5M ordinary shares to BTIG\" data-tweet=\"$OXFD - Oxford Immunotec to sell 2.5M ordinary shares to BTIG https://seekingalpha.com/news/3289190-oxford-immunotec-to-sell-2_5m-ordinary-shares-to-btig?source=tweet\" data-url=\"https://seekingalpha.com/news/3289190-oxford-immunotec-to-sell-2_5m-ordinary-shares-to-btig\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289188\" data-ts=\"1502742482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRKR\" target=\"_blank\">PRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289188-parkervision-shares-up-after-q2-results-feature-smaller-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ParkerVision shares up after Q2 results feature smaller losses</a></h4><ul><li>ParkerVision (<a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a>) reports Q2 results with no reported revenue, compared to $250K consensus, and loss per share of $0.18 compared to the $0.24 loss per share consensus estimate. Note that consensus in this case is based on low analyst coverage.</li><li>ParkerVision began the quarter with $2.9M in cash and equivalents and ended with $852K. The company used $3.78M in net cash for operating activities, up from $2.96M in last year&rsquo;s quarter.</li><li>The company announces an At Market Issuance Sales Agreement with FBR Capital Markets &amp; Co. for common stock sales up to an aggregate of $4.4M.</li><li>Upcoming legislation update: infringement case against Qualcomm and Apple in Florida middle district reopened in May with Markman hearing scheduled for January; Infringement cases against LG and Apple for Qualcomm-based devices awaiting validity decision in Munich, Germany; German infringement case against Apple for Intel devices scheduled for November.</li><li><a href=\"https://seekingalpha.com/pr/16915158-parkervision-reports-second-quarter-2017-results\" target=\"_blank\">Press release</a></li><li>ParkerVision shares closed today&nbsp;<font color='green'>up 17.71%</font>&nbsp;and are&nbsp;<font color='green'>up 1.46%</font>&nbsp;aftermarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289134-parkervision-reports-q2-results\" target=\"_blank\">ParkerVision reports Q2 results</a> (Aug. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289188\" data-linked=\"ParkerVision shares up after Q2 results feature smaller losses\" data-tweet=\"$PRKR - ParkerVision shares up after Q2 results feature smaller losses https://seekingalpha.com/news/3289188-parkervision-shares-up-after-q2-results-feature-smaller-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3289188-parkervision-shares-up-after-q2-results-feature-smaller-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289186\" data-ts=\"1502742366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289186-energy-transfer-partners-to-launch-54m-unit-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Transfer Partners to launch 54M-unit offering</a></h4><ul>     <li>Energy Transfer Partners (ETP) <font color='red'>-4.2%</font>&nbsp;AH after commencing a 54M-unit <a href=\"https://seekingalpha.com/pr/16915257-energy-transfer-partners-announces-common-unit-offering\" target=\"_blank\">public offering</a>, with an underwriters option to purchase up to an additional 8.1M common units.</li>     <li>ETP plans to use the proceeds to pay down its       revolving credit facilities, to fund capex and for general partnership purposes.</li>     <li>ETP expects this offering will eliminate the need for additional equity issuances through mid-2018 to fund its current portfolio of development projects.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289186\" data-linked=\"Energy Transfer Partners to launch 54M-unit offering\" data-tweet=\"$ET - Energy Transfer Partners to launch 54M-unit offering https://seekingalpha.com/news/3289186-energy-transfer-partners-to-launch-54m-unit-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3289186-energy-transfer-partners-to-launch-54m-unit-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>196&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289182\" data-ts=\"1502742152\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNAT\" target=\"_blank\">CNAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289182-conatus-completes-enrollment-in-mid-stage-nash-study-of-emricasan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Conatus completes enrollment in mid-stage NASH study of emricasan</a></h4><ul><li>Conatus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNAT' title='Conatus Pharmaceuticals'>CNAT</a>) hits the <a href=\"https://seekingalpha.com/pr/16915208-conatus-announces-completion-enrollment-encore-nf-phase-2b-clinical-trial-emricasan-patients\" target=\"_blank\">enrollment target</a> of ~300 participants in its Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02686762?cond=Nonalcoholic+Steatohepatitis&amp;intr=emricasan&amp;spons=conatus&amp;phase=1&amp;rank=1\" target=\"_blank\">ENCORE-NF</a>, assessing emricasan for the treatment of patients with nonalcoholic steatohepatitis &#40;NASH&#41; and stage 1 - 3 fibrosis.</li><li>The study will randomize patients 1:1:1 to receive 5 mg or 50 mg of emricasan or placebo twice daily for 72 weeks. The primary endpoint is biopsy-based improvement in fibrosis by at least one stage versus placebo using a scoring system called NASH CRN without worsening of steatohepatitis.</li><li>According to ClinicalTrials.gov, the estimated primary completion date is December 2018.</li><li>Fast Track-tagged&nbsp;<a href=\"http://www.conatuspharma.com/programs/\" target=\"_blank\">emricasan&nbsp;</a>inhibits a family of enzymes that modulate essential cellular functions called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Caspase\" target=\"_blank\">caspases</a>. The functions include those involved in apoptosis and inflammation. Caspases 3 and 7 are major players in apoptosis. These enzymes cleave a key protein called&nbsp;<a href=\"https://biocare.net/wp-content/uploads/3061.pdf\" target=\"_blank\">CK18</a>&nbsp;(cytokeratin-18), part of which is the small fragment cCK18, which correlates to the magnitude of hepatocyte apoptosis. Emricasan inhibits apoptosis regardless of the stimuli that causes it.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289182\" data-linked=\"Conatus completes enrollment in mid-stage NASH study of emricasan\" data-tweet=\"$CNAT - Conatus completes enrollment in mid-stage NASH study of emricasan https://seekingalpha.com/news/3289182-conatus-completes-enrollment-in-mid-stage-nash-study-of-emricasan?source=tweet\" data-url=\"https://seekingalpha.com/news/3289182-conatus-completes-enrollment-in-mid-stage-nash-study-of-emricasan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289174\" data-ts=\"1502741903\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289174-pandoraplus-6-names-slings-lynch-new-ceo-president\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora +6% as it names Sling&#39;s Lynch new CEO, president</a></h4><ul>     <li>Pandora (NYSE:<a href='https://seekingalpha.com/symbol/P' title='Pandora Media'>P</a>) is <font color='green'>up 6%</font> after hours as it <a href=\"https://seekingalpha.com/pr/16915195-pandora-announces-appointment-roger-lynch-chief-executive-officer\" target=\"_blank\">names Sling TV veteran Roger Lynch its new CEO</a> and president.</li>     <li>Lynch was the founding CEO of Sling TV, and previously served as executive VP of Advanced Technologies for Dish Network and EchoStar.</li>     <li>He's also joining the board. Interim CEO Naveen Chopra will return to his role as chief financial officer.</li>   <li>The company also added Snap chairman Michael Lynton to its board.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3289174\" data-linked=\"Pandora +6% as it names Sling&#39;s Lynch new CEO, president\" data-tweet=\"$P - Pandora +6% as it names Sling&#39;s Lynch new CEO, president https://seekingalpha.com/news/3289174-pandoraplus-6-names-slings-lynch-new-ceo-president?source=tweet\" data-url=\"https://seekingalpha.com/news/3289174-pandoraplus-6-names-slings-lynch-new-ceo-president\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289163\" data-ts=\"1502741699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMH\" target=\"_blank\">AMH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289163-american-homes-4-rent-raising-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Homes 4 Rent raising capital</a></h4><ul><li>The company has launched a secondary offering of 10M shares, with underwriter greenshoe of 1.5M shares.</li><li>Among the proceeds: Paying down debt, buying and renovating more houses, repurchasing shares (huh?).</li><li><a href='https://seekingalpha.com/symbol/AMH' title='American Homes 4 Rent'>AMH</a>&nbsp;<font color='red'>down 0.8%</font>&nbsp;after hours</li><li>Source: <a href=\"https://seekingalpha.com/pr/16915231-american-homes-4-rent-announces-public-offering-common-shares\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289163\" data-linked=\"American Homes 4 Rent raising capital\" data-tweet=\"$AMH - American Homes 4 Rent raising capital https://seekingalpha.com/news/3289163-american-homes-4-rent-raising-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3289163-american-homes-4-rent-raising-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289156\" data-ts=\"1502741573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289156-omeros-launches-3m-share-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros launches 3M-share stock offering</a></h4><ul><li>Omeros (NASDAQ:<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a>) <a href=\"https://seekingalpha.com/pr/16915193-omeros-announces-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of 3M shares of common stock. Underwriters over-allotment is an additional 450K shares. Price and terms have yet to be released.</li><li>Net proceeds will be used for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289156\" data-linked=\"Omeros launches 3M-share stock offering\" data-tweet=\"$OMER - Omeros launches 3M-share stock offering https://seekingalpha.com/news/3289156-omeros-launches-3m-share-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3289156-omeros-launches-3m-share-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289123\" data-ts=\"1502741170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289123-herbalife-under-pressure-on-chinas-plan-to-crack-down-on-multilevel-marketers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife under pressure on China&#39;s plan to crack down on multilevel marketers</a></h4><ul><li>Herbalife (<a href='https://seekingalpha.com/symbol/HLF' title='Herbalife Ltd.'>HLF</a> <font color='red'>-5.3%</font>) is tanking on more than triple normal volume on the news that Chinese officials plan to \"crack down\" on multilevel marketing organizations.</li><li>CNBC <a href=\"https://www.cnbc.com/2017/08/14/herbalife-shares-tank-by-6-percent-other-multilevel-marketing-firms-falling-as-well.html\" target=\"_blank\">reports</a> that four government departments in China will start to \"carry out special rectification activities\" (no specifics provided) to \"resolutely eradicate all kinds of MLM organizations.\"</li><li>China represent almost 20% of Herbalife's business. USANA Health Sciences and Nu Skin Enterprises have even greater exposure, 29% and 52%, respectively.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/USNA' title='USANA Health Sciences Inc.'>USNA</a> <font color='red'>-7.6%</font>)(<a href='https://seekingalpha.com/symbol/NUS' title='Nu Skin Enterprises Inc.'>NUS</a> <font color='red'>-7.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289123\" data-linked=\"Herbalife under pressure on China&#39;s plan to crack down on multilevel marketers\" data-tweet=\"$HLF $HLF $USNA - Herbalife under pressure on China&#39;s plan to crack down on multilevel marketers https://seekingalpha.com/news/3289123-herbalife-under-pressure-on-chinas-plan-to-crack-down-on-multilevel-marketers?source=tweet\" data-url=\"https://seekingalpha.com/news/3289123-herbalife-under-pressure-on-chinas-plan-to-crack-down-on-multilevel-marketers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289122\" data-ts=\"1502740725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IP\" target=\"_blank\">IP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289122-international-paperplus-2-following-da-davidson-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Paper +2% following DA Davidson upgrade</a></h4><ul>     <li>International Paper (<a href='https://seekingalpha.com/symbol/IP' title='International Paper Co.'>IP</a> <font color='green'>+1.9%</font>) is higher after DA&nbsp;Davidson <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+DA+Davidson+Upgrades+International+Paper+%28IP%29+to+Buy/13199473.html\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $62 price target, praising IP's successful containerboard price increases, strong box shipments and a rebound in its pulp business.</li>     <li>Davidson notes IP has successfully implemented two increases in containerboard prices since Q4 results, while box shipments rose 3% during H1; also, the firm thinks EBITDA of IP's pulp business should jump 42% in FY 2018 after fluff prices rose, and fluff looks poised to make up a higher percentage of the company's revenue going forward, boosting overall results.</li>     <li>IP's overall comp sales should resume increasing this quarter and profits should rise by 19% in Q3, the firm says, which would be the company's first increase in its profits in six quarters.</li>     <li>Other packaging makers also are higher: <a href='https://seekingalpha.com/symbol/KS' title='KapStone Paper and Packaging Corporation'>KS</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/WRK' title='WestRock Company'>WRK</a> <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/PKG' title='Packaging Corporation Of America'>PKG</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/CLW' title='Clearwater Paper Corporation'>CLW</a> <font color='green'>+1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289122\" data-linked=\"International Paper +2% following DA Davidson upgrade\" data-tweet=\"$IP $IP $KS - International Paper +2% following DA Davidson upgrade https://seekingalpha.com/news/3289122-international-paperplus-2-following-da-davidson-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3289122-international-paperplus-2-following-da-davidson-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289120\" data-ts=\"1502740661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289120-tech-sector-up-semiconductors-lead-way\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech sector up as semiconductors lead the way</a></h4><ul><li>The tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) trades&nbsp;<font color='green'>up 1.54%</font>&nbsp;near the end of the day driven by strength in semiconductor stocks.</li><li>The Philadelphia Semiconductor Index is&nbsp;<font color='green'>up 2.47%</font>&nbsp;with (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+7.9%</font>), (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+4.3%</font>), and (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a> <font color='green'>+4.4%</font>) as leaders.</li><li>Nvidia received a Buy rating from Argus, made it into Goldman Sachs&rsquo; recommended growth stocks list, and had its price target upgraded to $190 by Canaccord.</li><li>AMD gained on the commercial release of its Radeon RX Vega graphics cards and Radeon Packs.</li><li>Micron benefitted from Samsung increasing DRAM pricing in Q4.</li><li>Related ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3289068-goldman-sachs-recommends-growth-stocks-nvidia-autodesk\" target=\"_blank\">Goldman Sachs recommends growth stocks Nvidia, Autodesk</a> (Aug. 14)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289026-amd-announces-commercial-launch-radeon-graphics-cards\" target=\"_blank\">AMD announces commercial launch of Radeon graphics cards</a> (Aug. 14)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289006-dram-stocks-moving-samsung-prepares-raise-q4-prices\" target=\"_blank\">DRAM stocks moving as Samsung prepares to raise Q4 prices</a> (Aug. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289120\" data-linked=\"Tech sector up as semiconductors lead the way\" data-tweet=\"$NVDA $XLK $NVDA - Tech sector up as semiconductors lead the way https://seekingalpha.com/news/3289120-tech-sector-up-semiconductors-lead-way?source=tweet\" data-url=\"https://seekingalpha.com/news/3289120-tech-sector-up-semiconductors-lead-way\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289119\" data-ts=\"1502740566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289119-snap-bounces-off-all-time-lows-up-6_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap bounces off all-time lows, up 6.3%</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) hit an all-time low of $11.28 this morning, but like a cat has bounced to a <font color='green'>6.3% gain</font> as the close nears on heavy-volume and volatile trading amid a employee lockup expiration.</li>    <li>Whether short squeeze or just a relief rally after poor performance, Snap's also benefiting from CEO Evan Spiegel's pledge that he and co-founder Robert Murphy wouldn't be selling any of their stakes this year.</li>    <li>User growth is actually OK, says James Cakmak of Monness, Crespi, Hardt -- it's just that <a href=\"https://finance.yahoo.com/video/100-snaps-problems-self-inflicted-143400087.html\" target=\"_blank\">Snap's problems are 100% self-inflicted</a>. \"The users are there, and they're not monetizing; by definition, that's on them,\" he tells CNBC.</li><li>By design, the company's not going to get to Facebook's scale, he says. \"That's fine; as long as they're affluent customers that big advertisers and agencies want to go after, they should be able to monetize them, and we're not seeing that happen in North America.\"</li>    <li>As noted earlier, Dan Loeb and Third Point <a href=\"https://seekingalpha.com/news/3288912-new-positions-third-point\" target=\"_blank\">got out of their SNAP position</a> entirely during the quarter. Fidelity also <a href=\"https://www.bizjournals.com/boston/news/2017/08/14/fidelity-sells-off-more-than-half-its-stake-in.html\" target=\"_blank\">trimmed its stake by more than half</a>, ending the quarter with 15.2M shares (down 55% from March's end, but still remaining one of the company's top 10 shareholders).</li>    <li>T. Rowe Price boosted its stake during the quarter to 37.9M shares from 28.3M shares, and Vanguard and BlackRock also added to their stakes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289119\" data-linked=\"Snap bounces off all-time lows, up 6.3%\" data-tweet=\"$SNAP - Snap bounces off all-time lows, up 6.3% https://seekingalpha.com/news/3289119-snap-bounces-off-all-time-lows-up-6_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3289119-snap-bounces-off-all-time-lows-up-6_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289115\" data-ts=\"1502739677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSC-OLD\" target=\"_blank\">SSC-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289115-seven-stars-cloudminus-21-q2-loss-widens\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seven Stars Cloud -21% as Q2 loss widens</a></h4><ul>   <li>Seven Stars Cloud Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>) -- formerly Wecast Network, formerly You On Demand -- is <font color='red'>off 20.9%</font> today after posting <a href=\"https://seekingalpha.com/news/3288961-seven-stars-cloud-reports-q2-results\" target=\"_blank\">Q2 results</a> where losses widened as the company underwent another transformation, toward focusing on three cloud areas for commercial enterprises.</li>    <li>The company's working with a new business line vs. a year ago, and revenue changed accordingly (to $43.3M this quarter vs. a year-ago $1.5M).</li>    <li>Cost of revenue was also $43.3M, though.</li>    <li>Net loss widened to $3.7M from a loss of $1.6M.</li>    <li>The company also announced <a href=\"https://seekingalpha.com/pr/16914571-seven-stars-cloud-announces-2-new-separate-jv-partnerships\" target=\"_blank\">two new joint ventures</a>: one with Ocasia Group Holdings (a purchasing agent for major energy companies) and another with Beijing Urban Construction Holdings Materials Industry, a major national and provincial project builder.</li>    <li>Seven Stars Cloud pointed to them as the kind of partners it's now seeking, doing billions of dollars a year in purchasing and procurement turnover.</li>    <li><a href=\"http://corporate.sevenstarscloud.com/\" target=\"_blank\">Conference call</a> to come at 4:15 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16914634-seven-stars-cloud-reports-q2-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289115\" data-linked=\"Seven Stars Cloud -21% as Q2 loss widens\" data-tweet=\"$SSC-OLD - Seven Stars Cloud -21% as Q2 loss widens https://seekingalpha.com/news/3289115-seven-stars-cloudminus-21-q2-loss-widens?source=tweet\" data-url=\"https://seekingalpha.com/news/3289115-seven-stars-cloudminus-21-q2-loss-widens\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289111\" data-ts=\"1502739042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289111-pareteumplus-15-q2-beats-backlog-rises\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +15% as Q2 beats, backlog rises</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 15%</font> after it posted better-than-expected Q2 results along with a sharp gain in revenue backlog.</li>    <li>The company posted $3.2M in revenues, up 16% Q/Q and above expectations for $3.1M, and achieved positive EBITDA of $0.463M -- up 334% and vs. expectations for an EBITDA loss of $0.17M.</li>    <li>Meanwhile, revenue backlog rose 41% from the first quarter to hit $60M, up nearly threefold from the beginning of 2016.</li>    <li>Gross margins improved to 71% vs. 70% in Q1 and a year ago. Operating loss narrowed by 37% Q/Q to $1.2M, and net loss per share fell to $0.10 from a Q1 loss of $0.14.</li>    <li><a href=\"http://public.viavid.com/index.php?id=125843\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"http://www.pareteum.com/news/pareteum-announces-second-quarter-2017-financial-results/\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289111\" data-linked=\"Pareteum +15% as Q2 beats, backlog rises\" data-tweet=\"$TEUM - Pareteum +15% as Q2 beats, backlog rises https://seekingalpha.com/news/3289111-pareteumplus-15-q2-beats-backlog-rises?source=tweet\" data-url=\"https://seekingalpha.com/news/3289111-pareteumplus-15-q2-beats-backlog-rises\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289108\" data-ts=\"1502737781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMPI\" target=\"_blank\">DMPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289108-maxim-softens-view-on-delmar-pharma-questions-ability-to-raise-sufficient-capital-to-advance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxim softens view on DelMar Pharma, questions ability to raise sufficient capital to advance lead candidate VAL-083; shares slip 2%</a></h4><ul><li>In a rarity for uber-bull Maxim Group, it downgrades DelMar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='red'>-2.1%</font>) to Hold citing doubts about its ability to raise sufficient capital to advance lead candidate VAL-083, positioned to enter Phase 3 development in treatment-resistant brain cancer. It adds that management was hopeful that warrant exercises would raise an additional $10M in cash, but with exercise prices from $3.00 - 3.50 and the stock languishing at $1.40, this appears to be a remote near-term possibility.</li><li>Source: Bloomberg</li><li>See important&nbsp;<a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289108\" data-linked=\"Maxim softens view on DelMar Pharma, questions ability to raise sufficient capital to advance lead candidate VAL-083; shares slip 2%\" data-tweet=\"$DMPI - Maxim softens view on DelMar Pharma, questions ability to raise sufficient capital to advance lead candidate VAL-083; shares slip 2% https://seekingalpha.com/news/3289108-maxim-softens-view-on-delmar-pharma-questions-ability-to-raise-sufficient-capital-to-advance?source=tweet\" data-url=\"https://seekingalpha.com/news/3289108-maxim-softens-view-on-delmar-pharma-questions-ability-to-raise-sufficient-capital-to-advance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289107\" data-ts=\"1502737395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289107-banks-lead-s-and-p-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks lead S&amp;P rally</a></h4><ul><li>The broad banking sector (<a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a> <font color='green'>+2%</font>), (<a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> <font color='green'>+1.9%</font>) has about doubled the S&amp;P 500's&nbsp;<font color='green'>0.95% advance</font>&nbsp;today. The Financial Select SPDR ETF (<a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='green'>+1.3%</font>).</li><li>Trading volume, however - 20% below Friday's quiet action - can only be described as anemic. The financials were the 2nd-worst-performing sector during last week's selloff.</li><li>Among the movers: Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='green'>+2.3%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='green'>+2.4%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='green'>+2.3%</font>), Ameritrade (<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a> <font color='green'>+1.3%</font>), MetLife (<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='green'>+1.5%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289107\" data-linked=\"Banks lead S&amp;P rally\" data-tweet=\"$BAC $KRE $KBE - Banks lead S&amp;P rally https://seekingalpha.com/news/3289107-banks-lead-s-and-p-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3289107-banks-lead-s-and-p-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289106\" data-ts=\"1502737390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289106-amazon-announces-aws-macie-security-tool-glue-etl-service\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon announces AWS Macie security tool, Glue ETL service</a></h4><ul><li>Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) Web Services <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=176060&amp;p=RssLanding&amp;cat=news&amp;id=2293746\" target=\"_blank\">announces</a> Amazon Macie, a machine learning security service that helps prevent data loss and gives AWS a security tool similar to what Microsoft&rsquo;s Azure offers.</li><li>Macie recognizes sensitive data such as passwords, personally identifiable information, and intellectual property then issues alerts for abnormal access of the information.</li><li>The service seems based on the Macie tool from Harvest.ai, a start-up Amazon acquired early this year for $19M.</li><li>AWS has also made AWS Glue <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=176060&amp;p=RssLanding&amp;cat=news&amp;id=2293747\" target=\"_blank\">available</a> to all customers. Glue is a fully managed extract, transform, and load service that makes it easier for customers to prep and load data into the cloud.</li><li>Amazon shares are&nbsp;<font color='green'>up 1.41%.</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3234232-amazon-web-services-reportedly-acquires-data-security-startup-harvest-ai\" target=\"_blank\">Amazon Web Services reportedly acquires data security startup Harvest.ai</a> (Jan. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289106\" data-linked=\"Amazon announces AWS Macie security tool, Glue ETL service\" data-tweet=\"$AMZN - Amazon announces AWS Macie security tool, Glue ETL service https://seekingalpha.com/news/3289106-amazon-announces-aws-macie-security-tool-glue-etl-service?source=tweet\" data-url=\"https://seekingalpha.com/news/3289106-amazon-announces-aws-macie-security-tool-glue-etl-service\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289104\" data-ts=\"1502737074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289104-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='green'>+36%</font>. <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ZDGE' title='Zedge, Inc.'>ZDGE</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/IOTS' title='Adesto Technologies'>IOTS</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NLST' title='Netlist, Inc.'>OTC:NLST</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289104\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$CRDS $PRKR $TEUM - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3289104-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289104-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289099\" data-ts=\"1502735319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLEX\" target=\"_blank\">LLEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289099-lillis-energy-reports-strong-initial-production-growth-in-delaware-basin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lillis Energy reports strong initial production growth in Delaware Basin</a></h4><ul>     <li>Lillis Energy (<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-3.7%</font>) surrenders early gains and is now in the red after saying initial production from its recently drilled wells in the Delaware Basin in Texas <a href=\"https://seekingalpha.com/pr/16914422-lilis-energy-provides-second-quarter-operations-corporate-update\" target=\"_blank\">exceeded internal projections</a>.</li>     <li>LLEX says its three new wells averaged a combined 1,916 net boe/day during June and grew to 2,674 net boe/day through last Monday, Aug. 7, and CEO Jim Linville says he is confident a fourth well, known as the Lion, \"is on track to repeat similar results.\"</li>     <li>LLEX also says it has entered into a 10-year gas gathering, processing and purchase <a href=\"https://seekingalpha.com/pr/16914421-lilis-energy-lucid-energy-group-enter-long-term-gas-gathering-processing-purchase-agreement\" target=\"_blank\">agreement</a> with Lucid Energy Delaware to support LLEX's drilling program in the Delaware Basin.</li>     <li>Following the announcements, SunTrust analysts began covering LLEX with a <a href=\"https://www.streetinsider.com/Analyst+Comments/SunTrust+Robinson+Humphrey+Starts+Lilis+Energy+%28LLEX%29+at+Buy/13199795.html\" target=\"_blank\">Buy rating</a> and $7 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289099\" data-linked=\"Lillis Energy reports strong initial production growth in Delaware Basin\" data-tweet=\"$LLEX - Lillis Energy reports strong initial production growth in Delaware Basin https://seekingalpha.com/news/3289099-lillis-energy-reports-strong-initial-production-growth-in-delaware-basin?source=tweet\" data-url=\"https://seekingalpha.com/news/3289099-lillis-energy-reports-strong-initial-production-growth-in-delaware-basin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289094\" data-ts=\"1502734522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289094-apple-discusses-bringing-watch-to-aetna-members\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple discusses bringing Watch to Aetna members</a></h4><ul><li>        <a href=\"https://www.cnbc.com/2017/08/14/apple-aetna-secret-meetings-to-bring-apple-watch-to-millions-more.html\" target=\"_blank\">CNBC</a> reports that Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) and Aetna (NYSE:<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a>) held secret talks last week to discuss bringing the Apple Watch to the health insurer&rsquo;s 23M members.</li><li>               Aetna already offers an Apple Watch to 50K employees but now wants to extend a free or discounted wearable device as a membership perk.&nbsp;</li><li>               Apple fell to third in the global wearables market in Q2, <a href=\"https://www.strategyanalytics.com/strategy-analytics/blogs/devices/wearables/wearables/2017/08/03/xiaomi-becomes-world\" target=\"_blank\">according</a> to Strategy Analytics. Xiaomi topped the market with 3.7M shipments, Fitbit followed with 3.4M, and Apple shipped 2.8M units.&nbsp;</li><li>               Apple shares are&nbsp;<font color='green'>up 1.67%</font>.&nbsp;</li><li>               Aetna shares are&nbsp;<font color='green'>up 2.24%</font>. &nbsp;&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288322-apple-comes-third-q2-wearable-band-shipments\" target=\"_blank\">Apple comes third in Q2 wearable band shipments</a> (Aug. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289094\" data-linked=\"Apple discusses bringing Watch to Aetna members\" data-tweet=\"$AAPL $AAPL $AET - Apple discusses bringing Watch to Aetna members https://seekingalpha.com/news/3289094-apple-discusses-bringing-watch-to-aetna-members?source=tweet\" data-url=\"https://seekingalpha.com/news/3289094-apple-discusses-bringing-watch-to-aetna-members\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289092\" data-ts=\"1502734220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPG\" target=\"_blank\">IPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289092-interpublic-groupplus-2_7-pivotal-boosts-rating-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpublic Group +2.7% as Pivotal boosts rating to Buy</a></h4><ul>   <li>Interpublic Group (NYSE:<a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a>) is <font color='green'>up 2.7%</font> today after an upgrade to Buy at Pivotal Research.</li>    <li>Analyst Brian Wieser joins mostly bullish sentiment on the stock, with nearly a dozen Buy ratings on the sell side. Jefferies Group reiterated its Buy after <a href=\"https://seekingalpha.com/news/3280964-interpublic-group-minus-10_2-percent-results-miss-low-estimates\" target=\"_blank\">last month's earnings report</a>, as did BMO Capital Markets, Argus and Telsey Advisory Group.</li>    <li>Flying in the face of those ratings last month was lone bear Atlantic Securities, which downgraded to Underweight after the results.</li>    <li>Wieser and Pivotal have a price target of $24 on IPG, implying 13% upside from here.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289092\" data-linked=\"Interpublic Group +2.7% as Pivotal boosts rating to Buy\" data-tweet=\"$IPG - Interpublic Group +2.7% as Pivotal boosts rating to Buy https://seekingalpha.com/news/3289092-interpublic-groupplus-2_7-pivotal-boosts-rating-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3289092-interpublic-groupplus-2_7-pivotal-boosts-rating-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289091\" data-ts=\"1502733654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289091-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TESO' title='Tesco Corporation'>TESO</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/PZE' title='Petrobras Argentina S.A.'>PZE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TANH' title='Tantech Holdings'>TANH</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> EXXI <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PES' title='Pioneer Energy Services'>PES</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ANW' title='Aegean Marine Petroleum Network Inc.'>OTC:ANW</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289091\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$TESO $PZE $CLMT - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3289091-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289091-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289089\" data-ts=\"1502732519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDLS\" target=\"_blank\">NDLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289089-noodles-recovers-from-post-earnings-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Noodles recovers from post-earnings slide</a></h4><ul> <li>Noodles (NASDAQ:<a href='https://seekingalpha.com/symbol/NDLS' title='Noodles & Company'>NDLS</a>) is <font color='green'>up 9.33%</font> as investors bid shares back to where they stood before the company's Q2 earnings report was released.</li> <li>During the restaurant operator's conference call, execs noted that online ordering and delivery programs are't cannibalizing sales and will be expanded to more stores.</li> <li><a href=\"https://www.sec.gov/Archives/edgar/data/1159159/000090266417003292/xslForm13F_X01/infotable.xml\" target=\"_blank\">Noodles earnings call transcript</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3288686-noodles-drops-earnings\" target=\"_blank\">Noodles drops off after earnings</a> (Aug. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289089\" data-linked=\"Noodles recovers from post-earnings slide\" data-tweet=\"$NDLS - Noodles recovers from post-earnings slide https://seekingalpha.com/news/3289089-noodles-recovers-from-post-earnings-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3289089-noodles-recovers-from-post-earnings-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289087\" data-ts=\"1502731807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289087-financials-top-5-gainers-losers-of-1-30-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:30 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BMA' title='Banco Macro S.A.'>BMA</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='green'>+11%</font>.<a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/IRS' title='IRSA Inversiones Y Representaciones S.A.'>IRS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289087\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:30 PM\" data-tweet=\"$BMA $SUPV $GGAL - Financials - Top 5 Gainers / Losers as of 1:30 PM https://seekingalpha.com/news/3289087-financials-top-5-gainers-losers-of-1-30-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289087-financials-top-5-gainers-losers-of-1-30-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289086\" data-ts=\"1502731739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEFF\" target=\"_blank\">NEFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289086-sunstate-is-likely-new-bidder-for-neff-keybanc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunstate is likely the new bidder for Neff - Keybanc</a></h4><ul><li>via Bloomberg</li><li>Sunstate is the most likely \"strategic bidder\" for Neff Corp. (<a href='https://seekingalpha.com/symbol/NEFF' title='Neff Corp.'>NEFF</a> <font color='green'>+18.5%</font>), says KeyBancs Joe Box, and it probably has financial backing after Sumitomo recently acquired an additional stake.</li><li>H&amp;E Equipment (<a href='https://seekingalpha.com/symbol/HEES' title='H&E Equipment Services, Inc.'>HEES</a> <font color='red'>-2.5%</font>) has five days to match or counter the new offer, and Box says the deal could still be accretive at $25.50 per share, but obviously not as much so.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288918-neff-informs-h-and-e-better-buyout-offer\" target=\"_blank\">Neff informs H&amp;E of better buyout offer</a> (Aug. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289086\" data-linked=\"Sunstate is likely the new bidder for Neff - Keybanc\" data-tweet=\"$NEFF $NEFF $HEES - Sunstate is likely the new bidder for Neff - Keybanc https://seekingalpha.com/news/3289086-sunstate-is-likely-new-bidder-for-neff-keybanc?source=tweet\" data-url=\"https://seekingalpha.com/news/3289086-sunstate-is-likely-new-bidder-for-neff-keybanc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289085\" data-ts=\"1502731571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289085-blue-apron-higher-after-jana-partners-discloses-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron higher after Jana Partners discloses stake</a></h4><ul><li>Blue Apron (<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='green'>+3.3%</font>) breaks higher after Jana Partners discloses that it holds a 2% stake in the company.</li><li>The activist firm has experience in the grocery sector, including barking at Whole Foods Market in the year before the Amazon buyout.</li><li><a href=\"https://www.sec.gov/Archives/edgar/data/1159159/000090266417003292/xslForm13F_X01/infotable.xml\" target=\"_blank\">SEC Form 13F</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3289085\" data-linked=\"Blue Apron higher after Jana Partners discloses stake\" data-tweet=\"$APRN - Blue Apron higher after Jana Partners discloses stake https://seekingalpha.com/news/3289085-blue-apron-higher-after-jana-partners-discloses-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3289085-blue-apron-higher-after-jana-partners-discloses-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289083\" data-ts=\"1502731214\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289083-omeros-oms721-continues-to-demonstrate-treatment-benefit-after-one-year-in-iga-nephropathy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros&#39; OMS721 continues to demonstrate treatment benefit after one year in IgA nephropathy patients; shares ahead 5%</a></h4><ul><li>The market's up move notwithstanding, Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+4.9%</font>) perks up, albeit on light volume, after the company <a href=\"https://seekingalpha.com/pr/16915028-omeros-data-show-continued-improvement-patients-iga-nephropathy-treated-oms721\" target=\"_blank\">announced </a>positive long-term data on OMS721 in patients with immunoglobulin A (IgA) nephropathy.</li><li>Three of the four patients in the Phase 2 clinical trial continued to experience substantial reductions in proteinuria (protein in the urine) one year after treatment.</li><li>Professor of renal medicine in the&nbsp;Department of Infection, Immunity &amp; Inflammation at&nbsp;University of Leicester Jonathan Barratt, Ph.D., F.R.C.P. says, &ldquo;The durable reduction in proteinuria that we&rsquo;re seeing with OMS721 for one year after cessation of treatment is unprecedented in my experience. With this one-year follow-up, we are also seeing improvement in eGFR, which usually takes significantly longer to be evident. Two of the four patients demonstrated a slight increase, with one of the patients showing an exciting response of 50 percent improvement.&rdquo;</li><li>A Phase 3 study is on tap for later this year.</li><li>Orphan Drug- and Breakthrough Therapy-tagged OMS721 binds to an enzyme called mannan-binding lectin-associated serine protease-2 (<a href=\"http://www.omeros.com/pipeline/masp.htm\" target=\"_blank\">MASP-2</a>) which plays a key role in the lectin pathway of the complement system, which is believed to contribute to significant tissue injury.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3214295-omeros-lead-product-candidate-successful-mid-stage-study-kidney-diseases-shares-ahead-20\" target=\"_blank\">Omeros' lead product candidate successful in mid-stage study in kidney diseases; shares ahead 20% premarket</a> (Oct. 17, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289083\" data-linked=\"Omeros&#39; OMS721 continues to demonstrate treatment benefit after one year in IgA nephropathy patients; shares ahead 5%\" data-tweet=\"$OMER - Omeros&#39; OMS721 continues to demonstrate treatment benefit after one year in IgA nephropathy patients; shares ahead 5% https://seekingalpha.com/news/3289083-omeros-oms721-continues-to-demonstrate-treatment-benefit-after-one-year-in-iga-nephropathy?source=tweet\" data-url=\"https://seekingalpha.com/news/3289083-omeros-oms721-continues-to-demonstrate-treatment-benefit-after-one-year-in-iga-nephropathy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289082\" data-ts=\"1502730396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289082-jd-com-pursues-alibaba-luxury-platform-creation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com pursues Alibaba with luxury platform creation</a></h4><ul>   <li>JD.com (<a href=\"http://seekingalpha.com/symbol/JD\" target=\"_blank\">JD</a> <font color='red'>-3.5%</font>) plans to expand into an <a href=\"https://www.wsj.com/articles/jd-com-to-open-luxury-online-retail-site-rivaling-alibaba-1502720665\" target=\"_blank\">online luxury platform</a>, an attempt to keep up with Alibaba (<a href=\"http://seekingalpha.com/symbol/BABA\" target=\"_blank\">BABA</a> <font color='green'>+1.7%</font>) in the race for high-end spending.</li>    <li>Alibaba launched its luxury-brand platform earlier this month; meanwhile, JD.com invested $400M in June for a stake in the UK's Farfetch, focused on high-end goods.</li>    <li>China's consumers account for 30% of luxury spending worldwide, and the time is right for Chinese platforms to move on the initiative with the government looking to stem capital outflows.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3289045-jd-com-minus-3_5-percent-despite-solid-beat-q2\" target=\"_blank\">JD.com -3.5% despite solid beat for Q2</a> (Aug. 14 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289082\" data-linked=\"JD.com pursues Alibaba with luxury platform creation\" data-tweet=\"$JD $JD $BABA - JD.com pursues Alibaba with luxury platform creation https://seekingalpha.com/news/3289082-jd-com-pursues-alibaba-luxury-platform-creation?source=tweet\" data-url=\"https://seekingalpha.com/news/3289082-jd-com-pursues-alibaba-luxury-platform-creation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289079\" data-ts=\"1502729606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289079-myokardia-closes-equity-offering-gross-proceeds-almost-143m-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia closes equity offering, gross proceeds almost $143M; shares up 2%</a></h4><ul><li>MyoKardia (<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a> <font color='green'>+1.8%</font>) has <a href=\"https://seekingalpha.com/pr/16914943-myokardia-announces-closing-public-offering-common-stock-including-full-exercise-option\" target=\"_blank\">closed </a>its public offering of 4.025M shares of common stock at $35.50 per share, including underwriters' full exercise of their over-allotment of 525K shares. Gross proceeds were ~$142.9M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3287337-myokardia-prices-stock-offering-35_50\" target=\"_blank\">MyoKardia prices stock offering at $35.50</a> (Aug. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289079\" data-linked=\"MyoKardia closes equity offering, gross proceeds almost $143M; shares up 2%\" data-tweet=\"$MYOK - MyoKardia closes equity offering, gross proceeds almost $143M; shares up 2% https://seekingalpha.com/news/3289079-myokardia-closes-equity-offering-gross-proceeds-almost-143m-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3289079-myokardia-closes-equity-offering-gross-proceeds-almost-143m-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289077\" data-ts=\"1502729296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRX\" target=\"_blank\">BRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289077-strip-centers-over-malls-brixmor-upgraded-mizuho\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strip centers over malls - Brixmor upgraded at Mizuho</a></h4><ul><li>The common wisdom in age of Amazon says high-end malls located in well-to-do-areas and offering more in the way of \"experiences\" will hold up better than strip centers. Mizuho's Haendel St. Juste <a href=\"http://www.barrons.com/articles/contrarian-play-buy-strip-center-reits-over-malls-1502726090?mod=hp_RTA&amp;\" target=\"_blank\">takes exception, noting </a>malls have higher occupancy costs and much greater apparel exposure.</li><li>While strip centers look to have bottomed in Q2, malls have further to fall, he argues.</li><li>Liking its favorable valuation and its lower rents, he upgrades Brixmor Property Group (<a href='https://seekingalpha.com/symbol/BRX' title='Brixmor Property Group Inc.'>BRX</a> <font color='green'>+2.2%</font>) to Buy from Neutral. The $22 price target is about&nbsp;<font color='green'>10% upside&nbsp;</font>from the current level.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289077\" data-linked=\"Strip centers over malls - Brixmor upgraded at Mizuho\" data-tweet=\"$BRX - Strip centers over malls - Brixmor upgraded at Mizuho https://seekingalpha.com/news/3289077-strip-centers-over-malls-brixmor-upgraded-mizuho?source=tweet\" data-url=\"https://seekingalpha.com/news/3289077-strip-centers-over-malls-brixmor-upgraded-mizuho\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289075\" data-ts=\"1502729199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289075-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/PYDS' title='Payment Data Systems, Inc.'>PYDS</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NEFF' title='Neff Corp.'>NEFF</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/SKY' title='Skyline Champion Corp'>SKY</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/HLG' title='Hailiang Education Group Inc.'>HLG</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra'>FRTA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='red'>-16%</font>. EXXI <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/LNTH' title='Lantheus Holdings'>LNTH</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a> <font color='red'>-11%</font>. EBIO <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GEN' title='Genesis Healthcare, Inc.'>GEN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289075\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CRDS $CVM $USIO - Midday Gainers / Losers https://seekingalpha.com/news/3289075-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3289075-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289071\" data-ts=\"1502728368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289071-harmony-goldminus-4-after-warning-on-full-year-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmony Gold -4% after warning on full-year earnings</a></h4><ul>     <li>Harmony Gold (<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='red'>-3.8%</font>) says it expects FY 2017 net profit will come in <a href=\"http://www.foxbusiness.com/features/2017/08/14/harmony-gold-warns-on-fiscal-2017-earnings.html\" target=\"_blank\">lower than the year-ago period</a>, due to impairment charges and legal costs.</li>     <li>HMY sees EPS for the year ended June 30 of $0.05-$0.08, compared with $0.15 in FY 2016; excluding exceptional costs, HMY expects FY 2017 EPS of $0.20-$0.23,  higher than adjusted EPS of $0.15 recorded a year ago.</li>     <li>HMY expects to record an impairment of ~1.7B&nbsp;rand (US$131M) following its annual life-of-mine planning process and a provision of 917M rand ($70M) for a possible silicosis class action  settlement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289071\" data-linked=\"Harmony Gold -4% after warning on full-year earnings\" data-tweet=\"$HMY - Harmony Gold -4% after warning on full-year earnings https://seekingalpha.com/news/3289071-harmony-goldminus-4-after-warning-on-full-year-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3289071-harmony-goldminus-4-after-warning-on-full-year-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289068\" data-ts=\"1502727463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289068-goldman-sachs-recommends-growth-stocks-nvidia-autodesk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs recommends growth stocks Nvidia, Autodesk</a></h4><ul><li>        Goldman Sachs U.S. equity strategist David Kostin advises clients to buy growth stocks like Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) and Autodesk (NASDAQ:<a href='https://seekingalpha.com/symbol/ADSK' title='Autodesk, Inc.'>ADSK</a>), per <a href=\"https://www.cnbc.com/2017/08/14/goldman-buy-netflix-nvidia-and-other-growth-stocks-as-higher-rates-stifle-earnings.html\" target=\"_blank\">CNBC</a>.</li><li>               Kostin recommends the strategy because the higher interest rates next year could slow earnings expansion and enhance the value of growth stocks.&nbsp;</li><li>                  Kostin created a basket containing companies that allocate 90% of cash flow from operations to growth initiatives over the past three years.    </li><li>               Tech basket members, with YTD Return (and 3-yr growth investment ratio): Amazon, 28% (99%); Nvidia, 55% (105%); and Autodesk, 42% (161%).&nbsp;</li><li>               Meanwhile, Argus <a href=\"https://www.streetinsider.com/Analyst+Comments/NVIDIA+%28NVDA%29%3A+Selloff+Overdone%2C+Reiterate+Buy+-+Argus/13199896.html\" target=\"_blank\">reiterates</a> its Buy rating, calling the selloff overdone.&nbsp;</li><li>                  Nvidia shares are&nbsp;<font color='green'>up 5.82%</font>.    </li><li>               Autodesk shares are&nbsp;<font color='green'>up 0.89%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288756-barclays-increases-nvidia-price-target\" target=\"_blank\">Barclays increases Nvidia price target</a> (Aug. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289068\" data-linked=\"Goldman Sachs recommends growth stocks Nvidia, Autodesk\" data-tweet=\"$NVDA $NVDA $ADSK - Goldman Sachs recommends growth stocks Nvidia, Autodesk https://seekingalpha.com/news/3289068-goldman-sachs-recommends-growth-stocks-nvidia-autodesk?source=tweet\" data-url=\"https://seekingalpha.com/news/3289068-goldman-sachs-recommends-growth-stocks-nvidia-autodesk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289067\" data-ts=\"1502726445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289067-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/EFOI' title='Energy Focus, Inc.'>EFOI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='red'>-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289067\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SNAK $EFOI $FCAU - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3289067-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3289067-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289059\" data-ts=\"1502725533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERN\" target=\"_blank\">ERN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289059-erin-energy-starts-drilling-oyo-well-off-nigeria\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Erin Energy starts drilling at Oyo well off Nigeria</a></h4><ul>     <li>Erin Energy (<a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+8.3%</font>) is on the move after announcing the <a href=\"https://seekingalpha.com/pr/16914359-erin-energy-announces-spud-oyominus-9-well\" target=\"_blank\">start of drilling</a> of the Oyo-9 well offshore Nigeria, despite a dispute with Malaysian offshore contractor Bumi Armada.</li>     <li>ERN expects the well to take ~62 days to drill and complete, with the tie-in of the well to the floating production, storage and offloading unit for the start of production anticipated late in Q4; the well is expected to add 6K-7K boe/day to the field&rsquo;s current production.</li>     <li>ERN has been in dispute with the Malaysian contractor over delays in bareboat charter payments due by ERN as well as irregular payments on the operations and maintenance contract; ERN recently was allowed to flow its Oyo field oil into cargo tanks of the FPSO despite the debts.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289059\" data-linked=\"Erin Energy starts drilling at Oyo well off Nigeria\" data-tweet=\"$ERN - Erin Energy starts drilling at Oyo well off Nigeria https://seekingalpha.com/news/3289059-erin-energy-starts-drilling-oyo-well-off-nigeria?source=tweet\" data-url=\"https://seekingalpha.com/news/3289059-erin-energy-starts-drilling-oyo-well-off-nigeria\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289057\" data-ts=\"1502725382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PG\" target=\"_blank\">PG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289057-procter-gamble-digs-in-for-board-fight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Procter &amp; Gamble digs in for board fight</a></h4><ul> <li>Procter &amp; Gamble (<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='green'>+0.5%</font>) issues a letter to shareholders asking them to <a href=\"https://www.cnbc.com/2017/08/14/pg-urges-shareholders-to-vote-against-activist-investor-nelson-peltz.html\" target=\"_blank\">vote against</a> the bid by Trian Fund Management and Nelson Peltz to land a board seat.</li> <li>\"Mr. Peltz does not bring any new or needed skills to our Board. We believe that adding him to the Board would derail the very significant value creation progress we are making,\" reads the P&amp;G missive.</li><li>The company's annual meeting is expected to occur in October.</li> <li>Shares of P&amp;G are <font color='green'>up 5.42</font>% over the last 52 weeks to trail the S&amp;P 500 Index by a wide margin.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289057\" data-linked=\"Procter &amp; Gamble digs in for board fight\" data-tweet=\"$PG - Procter &amp; Gamble digs in for board fight https://seekingalpha.com/news/3289057-procter-gamble-digs-in-for-board-fight?source=tweet\" data-url=\"https://seekingalpha.com/news/3289057-procter-gamble-digs-in-for-board-fight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289056\" data-ts=\"1502725369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CERC\" target=\"_blank\">CERC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289056-cerecor-chief-retires-today-shares-ahead-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cerecor chief retires today; shares ahead 3%</a></h4><ul><li>Cerecor (<a href='https://seekingalpha.com/symbol/CERC' title='Cerecor'>CERC</a> <font color='green'>+2.9%</font>) President &amp; CEO Dr. Uli Hacksell <a href=\"https://seekingalpha.com/pr/16914549-cerecor-inc-announces-retirement-dr-uli-hacksell-president-chief-executive-officer\" target=\"_blank\">retires </a>effective today. Chief Business Officer John Kaiser will take over on an interim basis until a permanent CEO is appointed. Dr. Hacksell will continue as Chairman of the Board.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289056\" data-linked=\"Cerecor chief retires today; shares ahead 3%\" data-tweet=\"$CERC - Cerecor chief retires today; shares ahead 3% https://seekingalpha.com/news/3289056-cerecor-chief-retires-today-shares-ahead-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3289056-cerecor-chief-retires-today-shares-ahead-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289046\" data-ts=\"1502724086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RETA\" target=\"_blank\">RETA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289046-fda-signs-off-on-endpoint-for-reatas-mid-stage-study-of-omaveloxolone-in-rare-inherited-nerve\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA signs off on endpoint for Reata&#39;s mid-stage study of omaveloxolone in rare inherited nerve disorder; shares up 3%</a></h4><ul><li>Reata Pharmaceuticals (<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a> <font color='green'>+2.7%</font>) <a href=\"https://seekingalpha.com/pr/16914402-fda-confirms-use-mfars-primary-endpoint-part-2-moxie-trial-can-support-approval-omaveloxolone\" target=\"_blank\">announces </a>that the FDA has agreed that a rating scale called mFARS (modified Friedreich's Ataxia Rating Scale) is an acceptable endpoint for the second part of its Phase 2 clinical trial, MOXIe, assessing omaveloxolone in patients with <a href=\"http://www.curefa.org/whatis\" target=\"_blank\">Friedreich's Ataxia</a> &#40;FA&#41;, a rare inherited nervous system disorder characterized by impaired muscle coordination that worsens over time. The company believes the endpoint presents the opportunity of full approval if the results are robust.</li><li>Part 2 of <a href=\"https://clinicaltrials.gov/ct2/show/NCT02255435?titles=moxie&amp;spons=reata+pharmaceuticals&amp;rank=1\" target=\"_blank\">MOXIe </a>(the first part was a dose-escalation study) will randomize ~100 FA patients who will either receive 150 mg of omaveloxolone or placebo. The primary endpoint will be the change from baseline in mFARS at week 48 compared to placebo.</li><li>Dosing should commence later this year. According to ClinicalTrials.gov, the estimated primary completion date is February 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289046\" data-linked=\"FDA signs off on endpoint for Reata&#39;s mid-stage study of omaveloxolone in rare inherited nerve disorder; shares up 3%\" data-tweet=\"$RETA - FDA signs off on endpoint for Reata&#39;s mid-stage study of omaveloxolone in rare inherited nerve disorder; shares up 3% https://seekingalpha.com/news/3289046-fda-signs-off-on-endpoint-for-reatas-mid-stage-study-of-omaveloxolone-in-rare-inherited-nerve?source=tweet\" data-url=\"https://seekingalpha.com/news/3289046-fda-signs-off-on-endpoint-for-reatas-mid-stage-study-of-omaveloxolone-in-rare-inherited-nerve\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289045\" data-ts=\"1502723955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289045-jd-comminus-3_5-despite-solid-beat-for-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com -3.5% despite solid beat for Q2</a></h4><ul>   <li>JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a>) is <font color='red'>3.5% lower</font> following a <a href=\"https://seekingalpha.com/news/3288835-jd-com-beats-0_02-beats-revenue\" target=\"_blank\">Q2 earnings report</a> that beat expectations on top and bottom lines with strong revenue growth, but indicated some quarterly slowdown ahead.</li>    <li>The company swung to a net loss from continuing operations of 287M yuan (about $42.3M), from a year-ago gain of 127.6M yuan. But net income on a non-GAAP basis rose 59% to 976.5M yuan (about $144.1M.).</li>    <li>Non-GAAP operating margin was just 0.6%, however.</li>    <li>Operating cash flow rose more than sixfold to 26.6B yuan ($3.9B), and free cash flow was up 214% to 28.9B yuan ($4.3B).</li>    <li>For Q3, it's guiding to revenues of 81.8B yuan to 84.2B yuan (growth of 36-40% Y/Y); in line with consensus for 82.49B yuan but representing a sequential drop of 9.7-12.2%.</li>    <li><a href=\"https://seekingalpha.com/pr/16914275-jd-com-announces-second-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3289045\" data-linked=\"JD.com -3.5% despite solid beat for Q2\" data-tweet=\"$JD - JD.com -3.5% despite solid beat for Q2 https://seekingalpha.com/news/3289045-jd-comminus-3_5-despite-solid-beat-for-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3289045-jd-comminus-3_5-despite-solid-beat-for-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289018\" data-ts=\"1502722896\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289018-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/TBPH' title='Theravance Biopharma, Inc.'>TBPH</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/DRIO' title='DarioHealth Corp.'>DRIO</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DMPI' title='DelMar Pharmaceuticals, Inc.'>DMPI</a> <font color='red'>-9%</font>. EBIO <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289018\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CVM $EKSO $ZCOR - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3289018-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3289018-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289032\" data-ts=\"1502722080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCAU\" target=\"_blank\">FCAU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289032-auto-sector-jolted-merger-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto sector jolted by merger talk</a></h4><ul> <li>Shares of Fiat Chrysler Automobile (NYSE:<a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a>) <font color='green'>jump 7.46%</font> after <a href=\"http://www.autonews.com/article/20170814/OEM/170819914/chinese-automakers-covet-fca\" target=\"_blank\">Automotive News</a> reports the automaker rejected a takeover bid from a Chinese company. Great Wall Motor (<a href='https://seekingalpha.com/symbol/GWLLF' title='Great Wall Motor Company, Ltd.'>OTCPK:GWLLF</a>, <a href='https://seekingalpha.com/symbol/GWLLY' title='Great Wall Motor Company, Ltd. ADR'>OTCPK:GWLLY</a>) and Fiat JV partner Guangzhou Automobile Group (<a href='https://seekingalpha.com/symbol/GNZUF' title='Guangzhou Automobile Group Co., Ltd.'>OTCPK:GNZUF</a>, <a href='https://seekingalpha.com/symbol/GNZUY' title='Guangzhou Automobile Group Co., Ltd. ADR'>OTCPK:GNZUY</a>)&nbsp;are seen as the most likely <a href=\"https://www.usatoday.com/story/money/cars/2017/08/14/fiat-chrysler-chinese-automaker/564033001/\" target=\"_blank\">candidates</a> to have made the pitch.</li> <li>General Motors (<a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color='green'>+1.6%</font>), Ferrari (<a href='https://seekingalpha.com/symbol/RACE' title='Ferrari N.V.'>RACE</a> <font color='green'>+2.5%</font>) and Ford (<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a> <font color='green'>+1.4%</font>) are also making notable gains on the day amid the merger talk.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3288833-fiat-chrysler-soars-chinese-interest\" target=\"_blank\">Fiat Chrysler soars on Chinese interest</a> (Aug. 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289032\" data-linked=\"Auto sector jolted by merger talk\" data-tweet=\"$FCAU $FCAU $GWLLF - Auto sector jolted by merger talk https://seekingalpha.com/news/3289032-auto-sector-jolted-merger-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3289032-auto-sector-jolted-merger-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289030\" data-ts=\"1502721763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289030-amazon-announces-two-new-aws-customers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon announces two new AWS customers</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) announces two new customers for its Amazon Web Services platform.</li><li>               FICO has already <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=176060&amp;p=RssLanding&amp;cat=news&amp;id=2293694\" target=\"_blank\">migrated</a> several core applications and will migrate additional apps over the next three years.&nbsp;</li><li>               <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=176060&amp;p=RssLanding&amp;cat=news&amp;id=2293693\" target=\"_blank\">Hulu</a> will use AWS for its new over-the-top live TV service. Competitor Netflix is also an AWS customer.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.68%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3287682-aws-moves-one-step-closer-kubernetes-support\" target=\"_blank\">AWS moves one step closer to Kubernetes support</a> (Aug. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289030\" data-linked=\"Amazon announces two new AWS customers\" data-tweet=\"$AMZN - Amazon announces two new AWS customers https://seekingalpha.com/news/3289030-amazon-announces-two-new-aws-customers?source=tweet\" data-url=\"https://seekingalpha.com/news/3289030-amazon-announces-two-new-aws-customers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289028\" data-ts=\"1502721097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFSCF\" target=\"_blank\">PFSCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289028-prometic-life-sci-inks-jv-and-license-deal-in-china-for-three-pipeline-candidates-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prometic Life Sci inks JV and license deal in China for three pipeline candidates; investors unimpressed, shares off 2%</a></h4><ul><li>Prometic Life Sciences (<a href='https://seekingalpha.com/symbol/PFSCF' title='ProMetic Life Sciences Inc.'>OTCQX:PFSCF</a> <font color='red'>-2.4%</font>) enters into licensing <a href=\"https://seekingalpha.com/pr/16914325-prometic-shenzhen-royal-asset-management-close-transaction-joint-venture-licensing-rights\" target=\"_blank\">agreements </a>with affiliates of Shenzhen Royal Asset Management Co., Ltd., related to its previously announced joint venture. The new contracts cover the development, manufacturing and commercialization of PBI-4050, PBI-4547 and PBI-4425 in China. A new subsidiary has been formed, Prometic ChinaCo, whose initial focus will be on pulmonary and liver fibrosis.</li><li>Under the terms of the deal, Shenzhen will provide $33M in funding, $23M of which will be deployed in H2, followed by additional tranches next year. Shenzhen's ownership stake in Prometic ChinaCo will increase to as high as 25% when the funding is completed.</li><li>Prometic ChinaCo will be able to extend sub-licenses in China and will receive royalties on net sales from such agreements.</li><li>PBI-4050 and PBI-4547 are candidates to treat fibrosis. PBI-4425, an analogue of PBI-4050, is a candidate to treat pulmonary emphysema and cutaneous hyperplasia (pink/red bumps on the skin).</li></ul><div class=\"tiny-share-widget\" data-id=\"3289028\" data-linked=\"Prometic Life Sci inks JV and license deal in China for three pipeline candidates; investors unimpressed, shares off 2%\" data-tweet=\"$PFSCF - Prometic Life Sci inks JV and license deal in China for three pipeline candidates; investors unimpressed, shares off 2% https://seekingalpha.com/news/3289028-prometic-life-sci-inks-jv-and-license-deal-in-china-for-three-pipeline-candidates-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3289028-prometic-life-sci-inks-jv-and-license-deal-in-china-for-three-pipeline-candidates-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289027\" data-ts=\"1502721032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSIQ\" target=\"_blank\">CSIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289027-canadian-solarminus-5_5-after-guiding-q3-revenues-below-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Solar -5.5% after guiding Q3 revenues below consensus</a></h4><ul>     <li>Canadian Solar (<a href='https://seekingalpha.com/symbol/CSIQ' title='Canadian Solar Inc.'>CSIQ</a> <font color='red'>-5.5%</font>) plunges in early trading after reporting a slightly smaller than expected <a href=\"https://seekingalpha.com/news/3288852-canadian-solar-beats-0_01-beats-revenue\" target=\"_blank\">Q2 loss</a> but guiding Q3 revenues sharply below analyst expectations.</li>     <li>CSIQ  forecasts Q3 revenues of $805M-$825M vs. $1.04B analyst consensus estimate, with gross margin at 15%-17%; CSIQ reiterates its view for FY 2017 total module shipments at 6.0-6.5 GW.</li>     <li>For Q2, total solar module shipments were 1,745 MW, compared to 1,480 MW in Q1 and the company's Q2 guidance of 1,530-1,580 MW; Q2 gross margin was 15.9%, excluding benefits of two AD/CVD reversals, vs. 13.5% in Q1 and Q2 guidance of 13%-15%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289027\" data-linked=\"Canadian Solar -5.5% after guiding Q3 revenues below consensus\" data-tweet=\"$CSIQ - Canadian Solar -5.5% after guiding Q3 revenues below consensus https://seekingalpha.com/news/3289027-canadian-solarminus-5_5-after-guiding-q3-revenues-below-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3289027-canadian-solarminus-5_5-after-guiding-q3-revenues-below-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289026\" data-ts=\"1502720819\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289026-amd-announces-commercial-launch-of-radeon-graphics-cards\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD announces commercial launch of Radeon graphics cards</a></h4><ul><li>        Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) announces the commercial launch of its Radeon RX Vega graphics cards at global e-tail outlets.</li><li>               The Radeon RX Vega 64 air-cooled cards retail for $499.&nbsp;</li><li>               Limited edition Radeon Packs also available with the Black Pack containing the Radeon RX Vega 64 for $599 and the Aqua Pack featuring the Radeon RX Vega 64 Liquid Cooled Edition for $699.&nbsp;</li><li>               The Radeon RX Vega 56 graphics cards will launch on August 28 for $399.&nbsp;</li><li>               <a href=\"http://ir.amd.com/phoenix.zhtml?c=74093&amp;p=RssLanding&amp;cat=news&amp;id=2293705\" target=\"_blank\">Press release</a>&nbsp;</li><li>AMD shares are&nbsp;<font color='green'>up 4.58%</font>.&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288236-amd-releases-two-models-anticipated-ryzen-threadripper-processors\" target=\"_blank\">AMD releases two models of anticipated Ryzen Threadripper processors</a> (Aug. 10)</li></ul> &nbsp;<br /><div class=\"tiny-share-widget\" data-id=\"3289026\" data-linked=\"AMD announces commercial launch of Radeon graphics cards\" data-tweet=\"$AMD - AMD announces commercial launch of Radeon graphics cards https://seekingalpha.com/news/3289026-amd-announces-commercial-launch-of-radeon-graphics-cards?source=tweet\" data-url=\"https://seekingalpha.com/news/3289026-amd-announces-commercial-launch-of-radeon-graphics-cards\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>134&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289025\" data-ts=\"1502720488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DANOY\" target=\"_blank\">DANOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289025-danone-higher-on-buyout-rumor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Danone higher on buyout rumor</a></h4><ul> <li>Danone (<a href='https://seekingalpha.com/symbol/DANOY' title='Danone ADR'>OTCQX:DANOY</a>) trades higher after the <em>New York Post</em> speculates that the company could be the next food name to land an acquisition offer.</li> <li>\"It could be bought by a Kraft or a Coke, and the French government would allow it,\" a tipster tells the publication.</li> <li>Shares of Danone are <font color='green'>up 2.37%</font> in Paris, while the U.S. ADRs are <font color='green'>2.05% higher</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289025\" data-linked=\"Danone higher on buyout rumor\" data-tweet=\"$DANOY - Danone higher on buyout rumor https://seekingalpha.com/news/3289025-danone-higher-on-buyout-rumor?source=tweet\" data-url=\"https://seekingalpha.com/news/3289025-danone-higher-on-buyout-rumor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289023\" data-ts=\"1502719912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289023-bernstein-says-google-pay-apple-3b-to-remain-iphone-search-engine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bernstein says Google could pay Apple $3B to remain iPhone search engine</a></h4><ul><li>        Bernstein says Google&nbsp;(<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>)&nbsp;will pay Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) $3B this year to remain the default search engine on iPhones and iPads, per <a href=\"https://www.cnbc.com/2017/08/14/google-paying-apple-3-billion-to-remain-default-search--bernstein.html\" target=\"_blank\">CNBC</a>.&nbsp;</li><li>               Google paid Apple $1B in 2014.&nbsp;</li><li>               The Google licensing payments are mostly profit for Apple and Bernstein estimates the payments could account for up to 5% of Apple&rsquo;s operating profits in 2017.&nbsp;</li><li>               Bernstein analyst A.M. Sacconaghi Jr. says Apple&rsquo;s products account for about half of Google&rsquo;s mobile search revenues but that Google could still walk away from the payments at some point. Google wouldn&rsquo;t walk unless sure that Apple would continue to include its search engine based purely on customer demand.&nbsp;&nbsp;</li><li>Apple shares are&nbsp;<font color='green'>up 1.19%</font>. Alphabet Class A shares are&nbsp;<font color='green'>up 0.87%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3289023\" data-linked=\"Bernstein says Google could pay Apple $3B to remain iPhone search engine\" data-tweet=\"$GOOG $GOOG $GOOGL - Bernstein says Google could pay Apple $3B to remain iPhone search engine https://seekingalpha.com/news/3289023-bernstein-says-google-pay-apple-3b-to-remain-iphone-search-engine?source=tweet\" data-url=\"https://seekingalpha.com/news/3289023-bernstein-says-google-pay-apple-3b-to-remain-iphone-search-engine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289022\" data-ts=\"1502719897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289022-spectrums-additional-late-stage-study-of-apaziquone-in-bladder-cancer-underway-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum&#39;s additional late-stage study of apaziquone in bladder cancer underway; shares up 5%</a></h4><ul><li>The first patient has been <a href=\"https://seekingalpha.com/pr/16914370-spectrum-pharmaceuticals-announces-initiation-registrational-phase-3-trial-qapzola-apaziquone\" target=\"_blank\">enrolled </a>in Spectrum Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color='green'>+5.1%</font>) Phase 3 clinical trial assessing Qapzola (apaziquone) in patients with low-to-intermediate risk non-muscle invasive bladder cancer as a surgical adjuvant in patients undergoing TURBT (transurethral resection of the bladder tumor).</li><li>The company received a CRL in November 2016 citing the need to conduct another late-stage study.</li><li>The primary endpoint of the 425-subject study is time to recurrence in up to five year. According to ClinicalTrials.gov, the estimated primary completion date is January 2020.</li><li><a href=\"http://www.sppirx.com/321-spectrum-products-late-stage-apaziquone.html\" target=\"_blank\">Apaziquone&nbsp;</a>is a prodrug that is activated by certain enzymes that are over-expressed in bladder cancer cells. The activation renders it a highly cytotoxic alkylating agent.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3225688-fda-rejects-spectrum-pharmas-nda-qapzola\" target=\"_blank\">FDA rejects Spectrum Pharma's NDA for QAPZOLA</a> (Nov. 18, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289022\" data-linked=\"Spectrum&#39;s additional late-stage study of apaziquone in bladder cancer underway; shares up 5%\" data-tweet=\"$SPPI - Spectrum&#39;s additional late-stage study of apaziquone in bladder cancer underway; shares up 5% https://seekingalpha.com/news/3289022-spectrums-additional-late-stage-study-of-apaziquone-in-bladder-cancer-underway-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3289022-spectrums-additional-late-stage-study-of-apaziquone-in-bladder-cancer-underway-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289015\" data-ts=\"1502719116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UIS\" target=\"_blank\">UIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289015-unisys-announces-new-vp-and-treasurer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unisys announces new VP and treasurer</a></h4><ul><li>        Unisys (NYSE:<a href='https://seekingalpha.com/symbol/UIS' title='Unisys Corporation'>UIS</a>) announces Shalabh Gupta has joined as VP and treasurer.</li><li>               Gupta succeeds Scott A. Battersby, leaving after 33 years with the company, and will report to senior VP and CFO Inder M. Singh.&nbsp;</li><li>               Gupta most recently served as VP and corporate treasurer for Avon Products and previously worked as treasurer for Sara Lee and Evraz NA.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16914683-unisys-names-shalabh-gupta-vice-president-treasurer\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Unisys shares are&nbsp;<font color='green'>up 3.23%.</font>&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3289015\" data-linked=\"Unisys announces new VP and treasurer\" data-tweet=\"$UIS - Unisys announces new VP and treasurer https://seekingalpha.com/news/3289015-unisys-announces-new-vp-and-treasurer?source=tweet\" data-url=\"https://seekingalpha.com/news/3289015-unisys-announces-new-vp-and-treasurer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289013\" data-ts=\"1502718907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HHS\" target=\"_blank\">HHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289013-harte-hanks-on-notice-from-nyse-over-share-price\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harte Hanks on notice from NYSE over share price</a></h4><ul>   <li>Harte Hanks (<a href=\"http://seekingalpha.com/symbol/HHS\" target=\"_blank\">HHS</a> <font color='green'>+4.7%</font>) has gotten a <a href=\"https://seekingalpha.com/pr/16914311-harte-hanks-receives-notice-non-compliance-new-york-stock-exchange\" target=\"_blank\">noncompliance notice</a> from the NYSE over its share price.</li>    <li>The company's average closing price as of a week ago had fallen below a $1.00 minimum for a consecutive 30 days.</li>    <li>It has six months to cure the issue by bringing its average share price back above $1.00; it's up today to $0.798.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289013\" data-linked=\"Harte Hanks on notice from NYSE over share price\" data-tweet=\"$HHS - Harte Hanks on notice from NYSE over share price https://seekingalpha.com/news/3289013-harte-hanks-on-notice-from-nyse-over-share-price?source=tweet\" data-url=\"https://seekingalpha.com/news/3289013-harte-hanks-on-notice-from-nyse-over-share-price\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289012\" data-ts=\"1502718889\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289012-biocept-inks-global-distribution-deal-for-blood-collection-tubes-vwr-commercial-launch-later\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept inks global distribution deal for blood collection tubes with VWR, commercial launch later this year; shares ahead 3%</a></h4><ul><li>Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+3.2%</font>) has <a href=\"https://seekingalpha.com/pr/16914551-biocept-enters-exclusive-distribution-agreement-global-laboratory-product-supplier-vwr\" target=\"_blank\">signed </a>an exclusive global distribution agreement (ex-China) with VWR International for its proprietary blood collection tubes which allow for the intact transport of liquid biopsy samples for research use only from around the world. Commercial launch will commence later in the year.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3289012\" data-linked=\"Biocept inks global distribution deal for blood collection tubes with VWR, commercial launch later this year; shares ahead 3%\" data-tweet=\"$BIOC - Biocept inks global distribution deal for blood collection tubes with VWR, commercial launch later this year; shares ahead 3% https://seekingalpha.com/news/3289012-biocept-inks-global-distribution-deal-for-blood-collection-tubes-vwr-commercial-launch-later?source=tweet\" data-url=\"https://seekingalpha.com/news/3289012-biocept-inks-global-distribution-deal-for-blood-collection-tubes-vwr-commercial-launch-later\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289007\" data-ts=\"1502717954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289007-j-c-penny-looks-to-claw-back-from-post-earnings-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penny looks to claw back from post-earnings slide</a></h4><ul> <li>Susquehanna thinks same-store sales will accelerate for J.C. Penney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>) after the the department store chain posted a sequential improvement in Q2.</li> <li>The fimr notes that early August sales are tracking favorably for JCP amid the back-to-school season.</li> <li>Source: Bloomberg</li><li>Shares of J.C. Penney are&nbsp;<font color='green'>up 0.55%</font>&nbsp;in early trading as they look to claw back from last week's sharp post-earnings slide that saw them fall to as low as $3.77.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288598-weak-profit-sends-j-c-penney-lower\" target=\"_blank\">Weak profit sends J.C. Penney lower</a> (Aug. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289007\" data-linked=\"J.C. Penny looks to claw back from post-earnings slide\" data-tweet=\"$JCP - J.C. Penny looks to claw back from post-earnings slide https://seekingalpha.com/news/3289007-j-c-penny-looks-to-claw-back-from-post-earnings-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3289007-j-c-penny-looks-to-claw-back-from-post-earnings-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289001\" data-ts=\"1502717426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289001-applied-optoplus-3_6-key-add-capital-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Opto +3.6% as key add at Capital Growth</a></h4><ul>    <li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) is <font color='green'>up 3.6%</font> premarket after Ken Heebner and his Capital Growth Management raised its stake in the company.</li>    <li><a href=\"https://www.sec.gov/Archives/edgar/data/868491/000086849117000009/xslForm13F_X01/copyofcgm13f06302017inform.xml\" target=\"_blank\">Capital Growth's 13F</a> also shows adds in Alibaba (<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>, <font color='green'>up 1.9%</font> premarket) while top sales include Lennar (NYSE:<a href='https://seekingalpha.com/symbol/LEN' title='Lennar Corporation'>LEN</a>) and Toll Brothers (NYSE:<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3289001\" data-linked=\"Applied Opto +3.6% as key add at Capital Growth\" data-tweet=\"$AAOI $AAOI $BABA - Applied Opto +3.6% as key add at Capital Growth https://seekingalpha.com/news/3289001-applied-optoplus-3_6-key-add-capital-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3289001-applied-optoplus-3_6-key-add-capital-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3289000\" data-ts=\"1502717339\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANTH\" target=\"_blank\">ANTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3289000-antheras-late-stage-study-of-sollpura-to-be-included-in-european-cf-network-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anthera&#39;s late-stage study of Sollpura to be included in European CF network; shares ahead 9% premarket</a></h4><ul><li>Thinly traded nano cap Anthera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16914621-anthera-pharmaceuticals-announces-result-phase-3-clinical-study-sollpura-will-included\" target=\"_blank\">announcement </a>that its Phase 3 RESULT study assessing Sollpura (liprotamase) for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network Executive Committee, a decision that should expedite patient recruitment.</li><li>Top-line are expected as early as year-end.</li><li><a href=\"https://www.anthera.com/product-pipeline/sollpura/\" target=\"_blank\">Sollpura&nbsp;</a>is a non-porcine pancreatic enzyme replacement therapy &#40;PERT&#41; containing a proprietary engineered cross-linked formulation of crystalline lipase, crystalline protease and amorphous amylase. The company says its solubility and stability offers a more patient-friendly alternative for those who cannot swallow multiple pills or require gastric tubes in order to maintain their nutritional health.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3254289-antheras-sollpura-par-pancreaze-extension-phase-late-stage-study-certain-cf-patients-shares\" target=\"_blank\">Anthera's Sollpura on par with Pancreaze in extension phase of late-stage study in certain CF patients; shares ahead 9% after hours</a> (March 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3289000\" data-linked=\"Anthera&#39;s late-stage study of Sollpura to be included in European CF network; shares ahead 9% premarket\" data-tweet=\"$ANTH - Anthera&#39;s late-stage study of Sollpura to be included in European CF network; shares ahead 9% premarket https://seekingalpha.com/news/3289000-antheras-late-stage-study-of-sollpura-to-be-included-in-european-cf-network-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3289000-antheras-late-stage-study-of-sollpura-to-be-included-in-european-cf-network-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288993\" data-ts=\"1502716943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288993-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='green'>+56%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3288908-fda-removes-clinical-hold-cel-scis-late-stage-study-multikine-head-neck-cancer-shares-ahead\" target=\"_blank\">announcement&nbsp;</a>that the FDA has removed the clinical hold on its Phase 3 clinical trial assessing Multikine.</li><li><a href='https://seekingalpha.com/symbol/CRDS' title='Crossroads Systems, Inc.'>CRDS</a> <font color='green'>+25%</font>.</li><li><a href='https://seekingalpha.com/symbol/NEFF' title='Neff Corp.'>NEFF</a> <font color='green'>+16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3288918-neff-informs-h-and-e-better-buyout-offer\" target=\"_blank\">receiving</a> offer from a strategic bidder to acquire all outstanding shares of the company for $25 per share in cash.</li><li><a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a> <font color='green'>+10%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3288952-fda-accepts-lipocines-resubmitted-marketing-application-trt-med-tlando-action-date-february-8\" target=\"_blank\">announcement&nbsp;</a>that the FDA has accepted for review its resubmitted New Drug Application &#40;NDA&#41; seeking approval for TLANDO.</li><li><a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a> <font color='green'>+11%</font>&nbsp;on&nbsp;&nbsp;Overweight <a href=\"https://seekingalpha.com/news/3288939-premarket-analyst-action-healthcare\" target=\"_blank\">rating</a> and $7 (586% upside)&nbsp;price target by Cantor Fitzgerald.</li><li><a href='https://seekingalpha.com/symbol/ANTH' title='Anthera Pharmaceuticals, Inc.'>OTC:ANTH</a> <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/symbol/FCAU' title='Fiat Chrysler Automobiles NV'>FCAU</a> <font color='green'>+6%</font>&nbsp;on Chinese <a href=\"https://seekingalpha.com/news/3288833\" target=\"_blank\">interest</a>.</li><li><a href='https://seekingalpha.com/symbol/TSEM' title='Tower Semiconductor Ltd.'>TSEM</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3288911-towerjazz-announces-use-tech-toyota-sensor\" target=\"_blank\">announcing</a> use of its tech in Toyota sensor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3288993\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$CVM $CRDS $NEFF - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3288993-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3288993-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288985\" data-ts=\"1502716610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288985-vmware-announces-preliminary-q2-results-updates-fy-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VMware announces preliminary Q2 results, updates FY guidance</a></h4><ul><li>VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>) <a href=\"https://seekingalpha.com/pr/16914648-vmware-reports-preliminary-results-fiscal-2018-second-quarter\" target=\"_blank\">announces</a>&nbsp;preliminary Q2 results and a senior notes offering.</li><li>Q2 results: revenue, $1.89B to $1.9B (+11.9% to 12.6% Y/Y; consensus: $1.86B); license revenue, $727M to $737M (+12.9% to 14.4%); GAAP operating margin, 30.5% to 31.1%; diluted EPS, $1.15 to $1.19 (consensus:$1.13).</li><li>FY18 guidance increased: revenue, $7.83B (+10%; consensus: $7.62B); license revenue, $3.08B (+10%); GAAP operating margin, 20% to 21%; diluted EPS, $5.08 (consensus: $4.93B).</li><li>Additional results will report on August 24.</li><li>VMware also <a href=\"http://ir.vmware.com/overview/press-releases/press-release-details/2017/VMware-Announces-Offering-of-Senior-Notes/default.aspx\" target=\"_blank\">announces</a> a $1B stock repurchase authorization, which adds to the previously announced $1.2B repurchase program for this year.</li><li>VMware shares are&nbsp;<font color='green'>up 4.4%</font>&nbsp;premarket.</li><li>Correction: Post updated to correct Q2 EPS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3288985\" data-linked=\"VMware announces preliminary Q2 results, updates FY guidance\" data-tweet=\"$VMW - VMware announces preliminary Q2 results, updates FY guidance https://seekingalpha.com/news/3288985-vmware-announces-preliminary-q2-results-updates-fy-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3288985-vmware-announces-preliminary-q2-results-updates-fy-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288984\" data-ts=\"1502716480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EKSO\" target=\"_blank\">EKSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288984-ekso-commences-34m-rights-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ekso commences $34M rights offering</a></h4><ul><li>Ekso Bionics Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a>) <a href=\"https://seekingalpha.com/pr/16914658-ekso-bionics-announces-commencement-34-million-rights-offering\" target=\"_blank\">starts </a>its previously announced rights offering of up to 34M shares of common stock at $1 per share. Current stockholders and certain warrant holders are eligible to participate. Each holder of subscription rights with have the right to buy 1.1608 shares of common at a per-share price of $1.</li><li>Deadline to sign on is August 31.</li><li>Net proceeds will fund commercial activities, R&amp;D, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3288984\" data-linked=\"Ekso commences $34M rights offering\" data-tweet=\"$EKSO - Ekso commences $34M rights offering https://seekingalpha.com/news/3288984-ekso-commences-34m-rights-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3288984-ekso-commences-34m-rights-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288979\" data-ts=\"1502716222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288979-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/ZYNE' title='Zynerba Pharmaceuticals'>ZYNE</a>&nbsp;<font color='red'>-21%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3288886-zynerbas-lead-candidate-zyn002-flunks-mid-stage-study-osteoarthritis-associated-knee-pain\" target=\"_blank\">announcing</a> results from Phase 2 STOP trial assessing ZYN002.</li><li><a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3288844-sorl-auto-misses-0_02-misses-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/OPHT' title='Ophthotech Corporation'>OPHT</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3288878-ophthotechs-fovista-flunks-late-stage-wet-amd-shares-14-percent-premarket\" target=\"_blank\">announcing</a> results from third Phase 3 trial of Fovista in wet AMD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3288979\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$ZYNE $SORL $ISEE - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3288979-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3288979-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288972\" data-ts=\"1502715530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TESO\" target=\"_blank\">TESO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288972-nabors-industries-to-buy-tesco-in-all-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nabors Industries to buy Tesco in all-stock deal</a></h4><ul>     <li>Tesco (NASDAQ:<a href='https://seekingalpha.com/symbol/TESO' title='Tesco Corporation'>TESO</a>)&nbsp;<font color='green'>+11.5%</font> premarket after Nabors Industries (NYSE:<a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a>) <a href=\"https://seekingalpha.com/pr/16914308-tesco-corporation-enters-arrangement-agreement-nabors-industries-ltd-stock-stock-combination\" target=\"_blank\">agrees to acquire</a> the Canadian drilling equipment maker in an all-stock deal.</li>     <li>Tesco shareholders will be issued 0.68 NBR common shares for each Tesco share; the deal values Tesco at $4.62/share, a 19% premium to Friday's close, or ~$215M.</li>     <li>NBR says the acquisition will reinforce its position as a leading rig equipment and drilling automation provider by integrating Tesco&rsquo;s advanced tubular services technology and products into its global rig footprint and drilling services business.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3288972\" data-linked=\"Nabors Industries to buy Tesco in all-stock deal\" data-tweet=\"$TESO $TESO $NBR - Nabors Industries to buy Tesco in all-stock deal https://seekingalpha.com/news/3288972-nabors-industries-to-buy-tesco-in-all-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3288972-nabors-industries-to-buy-tesco-in-all-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288960\" data-ts=\"1502714722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYY\" target=\"_blank\">SYY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288960-on-syscos-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on SYSCO&#39;s Q4</a></h4><ul>     <li>SYSCO (NYSE:<a href='https://seekingalpha.com/symbol/SYY' title='Sysco Corporation'>SYY</a>) reports comparable sales rose 3.4% in <a href=\"https://seekingalpha.com/pr/16914534-sysco-reports-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Q4</a>.</li>     <li>U.S.&nbsp;foodservice operations sales decreased 3.8% to $9.8B.</li>     <li>International foodservice operations grew 80.4% to $2.73B.</li>     <li>SYGMA sales dropped 2% to $1.62B<em>.</em></li>     <li>Gross margin rate improved 80 bps to 19.14%.</li>     <li>Adjusted operating margin rate +2 bps to 4.62%.</li><li>SYY&nbsp;<font color='red'>-0.16%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3288960\" data-linked=\"More on SYSCO&#39;s Q4\" data-tweet=\"$SYY - More on SYSCO&#39;s Q4 https://seekingalpha.com/news/3288960-on-syscos-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3288960-on-syscos-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288952\" data-ts=\"1502714375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LPCN\" target=\"_blank\">LPCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288952-fda-accepts-lipocines-resubmitted-marketing-application-for-trt-med-tlando-action-date\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Lipocine&#39;s resubmitted marketing application for TRT med Tlando, action date February 8, 2018; shares ahead 9% premarket</a></h4><ul><li>Lipocine (NASDAQ:<a href='https://seekingalpha.com/symbol/LPCN' title='Lipocine Inc.'>LPCN</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16914500-lipocine-announces-fda-acknowledgement-tlando-lpcn-1021-nda-resubmission-pdufa-goal-date\" target=\"_blank\">announcement </a>that the FDA has accepted for review its resubmitted New Drug Application &#40;NDA&#41; seeking approval for TLANDO (formerly LPCN 1021) for testosterone replacement therapy &#40;TRT&#41;. The agency's action date is February 8, 2018.</li><li>The company received a CRL in June 2016 citing deficiencies in the dosing regimen.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3214270-lipocine-meets-fda-discuss-crl-new-clinical-trial-needed-validate-dosing-regimen-lpcn-1021\" target=\"_blank\">Lipocine meets with FDA to discuss CRL, new clinical trial needed to validate dosing regimen of LPCN 1021; shares ahead 12% premarket</a> (Oct. 17, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3288952\" data-linked=\"FDA accepts Lipocine&#39;s resubmitted marketing application for TRT med Tlando, action date February 8, 2018; shares ahead 9% premarket\" data-tweet=\"$LPCN - FDA accepts Lipocine&#39;s resubmitted marketing application for TRT med Tlando, action date February 8, 2018; shares ahead 9% premarket https://seekingalpha.com/news/3288952-fda-accepts-lipocines-resubmitted-marketing-application-for-trt-med-tlando-action-date?source=tweet\" data-url=\"https://seekingalpha.com/news/3288952-fda-accepts-lipocines-resubmitted-marketing-application-for-trt-med-tlando-action-date\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288940\" data-ts=\"1502713441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SORL\" target=\"_blank\">SORL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288940-weak-guidance-sends-sorl-auto-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weak guidance sends SORL Auto lower</a></h4><ul> <li>SORL Auto Parts (NASDAQ:<a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a>) slides after releasing Q2 results and setting guidance.</li> <li>The company expects full-year sales of $315M vs. $315M consensus and net income of $27.5M.</li> <li>SORL <font color='red'>-14.35%</font> premarket to $5.97 vs. a 52-week trading range of $1.83 to $9.74.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288844-sorl-auto-misses-0_02-misses-revenue\" target=\"_blank\">SORL Auto misses by $0.02, misses on revenue</a> (Aug. 14)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288850-sorl-autos-q2\" target=\"_blank\">More on SORL Auto's Q2</a> (Aug. 14)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3288940\" data-linked=\"Weak guidance sends SORL Auto lower\" data-tweet=\"$SORL - Weak guidance sends SORL Auto lower https://seekingalpha.com/news/3288940-weak-guidance-sends-sorl-auto-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3288940-weak-guidance-sends-sorl-auto-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288939\" data-ts=\"1502713422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KALA\" target=\"_blank\">KALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288939-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Kala Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALA' title='Kala Pharmaceuticals'>KALA</a>) initiated with Buy rating and $33 (65% upside) price target by Bank of America Merrill Lynch. Initiated with Outperform rating and $46 (130% upside) price target by Wedbush. Shares are up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Egalet (<a href='https://seekingalpha.com/symbol/EGLT' title='Egalet Ltd.'>OTC:EGLT</a>) resumed with Overweight rating and $7 (586% upside)&nbsp;price target by Cantor Fitzgerald. Shares up&nbsp;<font color='green'>8%</font>&nbsp;premarket.</li><li>BioDelivery Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a>) resumed with Overweight rating and $4.50 (53% upside) price target by Cantor Fitzgerald. Shares up&nbsp;<font color='green'>3%&nbsp;</font>premarket.</li><li>Calyxt (NASDAQ:<a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a>) initiated with Outperform rating and $17 (44% upside) price target by Wells Fargo.</li><li>STAAR Surgical (NASDAQ:<a href='https://seekingalpha.com/symbol/STAA' title='STAAR Surgical Company'>STAA</a>) price target raised to $13 (11% upside) by Benchmark citing bullish outlook in Asia and regulatory progress.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3288939\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$KALA $KALA $ZCOR - Premarket analyst action - healthcare https://seekingalpha.com/news/3288939-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3288939-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3288933\" data-ts=\"1502712707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OA\" target=\"_blank\">OA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3288933-orbital-atk-raise-argus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orbital ATK raise at Argus</a></h4><ul><li>Argus has <a href=\"https://www.benzinga.com/news/17/08/9923233/argus-upgrades-orbital-atk-to-buy\" target=\"_blank\">upgraded</a> Orbital ATK (NYSE:<a href='https://seekingalpha.com/symbol/OA' title='Orbital ATK, Inc.'>OA</a>) to Buy from Hold, based on valuation and belief that its cash flow can increase.</li><li>The firm also feels that the company will benefit from increased U.S. defense spending in 2017-2018 and set its price target at $120.</li><li>OA <font color='green'>+1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3288933\" data-linked=\"Orbital ATK raise at Argus\" data-tweet=\"$OA - Orbital ATK raise at Argus https://seekingalpha.com/news/3288933-orbital-atk-raise-argus?source=tweet\" data-url=\"https://seekingalpha.com/news/3288933-orbital-atk-raise-argus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}